KR102722620B1 - Manufacturing method of animal feed additives - Google Patents
Manufacturing method of animal feed additives Download PDFInfo
- Publication number
- KR102722620B1 KR102722620B1 KR1020230070071A KR20230070071A KR102722620B1 KR 102722620 B1 KR102722620 B1 KR 102722620B1 KR 1020230070071 A KR1020230070071 A KR 1020230070071A KR 20230070071 A KR20230070071 A KR 20230070071A KR 102722620 B1 KR102722620 B1 KR 102722620B1
- Authority
- KR
- South Korea
- Prior art keywords
- solution
- culture supernatant
- amino acid
- culture
- mineral
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 18
- 235000019730 animal feed additive Nutrition 0.000 title description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 138
- 239000011707 mineral Substances 0.000 claims abstract description 81
- 239000012228 culture supernatant Substances 0.000 claims abstract description 60
- 150000001413 amino acids Chemical class 0.000 claims abstract description 53
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 42
- 239000003674 animal food additive Substances 0.000 claims abstract description 25
- 241000894006 Bacteria Species 0.000 claims abstract description 24
- 238000004108 freeze drying Methods 0.000 claims abstract description 21
- 239000004310 lactic acid Substances 0.000 claims abstract description 21
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 21
- 244000063299 Bacillus subtilis Species 0.000 claims abstract description 20
- 235000014469 Bacillus subtilis Nutrition 0.000 claims abstract description 20
- 238000000034 method Methods 0.000 claims abstract description 16
- 238000012258 culturing Methods 0.000 claims abstract description 15
- 238000006243 chemical reaction Methods 0.000 claims abstract description 14
- 238000002156 mixing Methods 0.000 claims abstract description 11
- 239000000243 solution Substances 0.000 claims description 95
- 235000010755 mineral Nutrition 0.000 claims description 79
- 235000001014 amino acid Nutrition 0.000 claims description 50
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 27
- 239000000203 mixture Substances 0.000 claims description 23
- 230000012010 growth Effects 0.000 claims description 22
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 21
- 239000000843 powder Substances 0.000 claims description 21
- 239000004471 Glycine Substances 0.000 claims description 18
- 239000013535 sea water Substances 0.000 claims description 17
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 14
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 14
- 239000011575 calcium Substances 0.000 claims description 14
- 239000006185 dispersion Substances 0.000 claims description 14
- 239000008103 glucose Substances 0.000 claims description 14
- 235000013922 glutamic acid Nutrition 0.000 claims description 14
- 239000004220 glutamic acid Substances 0.000 claims description 14
- 239000011651 chromium Substances 0.000 claims description 12
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 11
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 11
- 229910052791 calcium Inorganic materials 0.000 claims description 11
- 239000011780 sodium chloride Substances 0.000 claims description 11
- 229940041514 candida albicans extract Drugs 0.000 claims description 10
- 229910052717 sulfur Inorganic materials 0.000 claims description 10
- 239000011593 sulfur Substances 0.000 claims description 10
- 239000012138 yeast extract Substances 0.000 claims description 10
- 239000012141 concentrate Substances 0.000 claims description 9
- 239000010949 copper Substances 0.000 claims description 9
- 229910052900 illite Inorganic materials 0.000 claims description 9
- VGIBGUSAECPPNB-UHFFFAOYSA-L nonaaluminum;magnesium;tripotassium;1,3-dioxido-2,4,5-trioxa-1,3-disilabicyclo[1.1.1]pentane;iron(2+);oxygen(2-);fluoride;hydroxide Chemical compound [OH-].[O-2].[O-2].[O-2].[O-2].[O-2].[F-].[Mg+2].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[K+].[K+].[K+].[Fe+2].O1[Si]2([O-])O[Si]1([O-])O2.O1[Si]2([O-])O[Si]1([O-])O2.O1[Si]2([O-])O[Si]1([O-])O2.O1[Si]2([O-])O[Si]1([O-])O2.O1[Si]2([O-])O[Si]1([O-])O2.O1[Si]2([O-])O[Si]1([O-])O2.O1[Si]2([O-])O[Si]1([O-])O2 VGIBGUSAECPPNB-UHFFFAOYSA-L 0.000 claims description 9
- 239000011669 selenium Substances 0.000 claims description 9
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 8
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims description 8
- 150000007524 organic acids Chemical class 0.000 claims description 8
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims description 7
- 229910052804 chromium Inorganic materials 0.000 claims description 7
- 235000019797 dipotassium phosphate Nutrition 0.000 claims description 7
- 229910000396 dipotassium phosphate Inorganic materials 0.000 claims description 7
- 238000002347 injection Methods 0.000 claims description 7
- 239000007924 injection Substances 0.000 claims description 7
- 239000011572 manganese Substances 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 6
- JBQYATWDVHIOAR-UHFFFAOYSA-N tellanylidenegermanium Chemical compound [Te]=[Ge] JBQYATWDVHIOAR-UHFFFAOYSA-N 0.000 claims description 6
- 239000010936 titanium Substances 0.000 claims description 6
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 5
- 229920002261 Corn starch Polymers 0.000 claims description 5
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 5
- 229910052802 copper Inorganic materials 0.000 claims description 5
- 239000008120 corn starch Substances 0.000 claims description 5
- 239000013538 functional additive Substances 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 239000003755 preservative agent Substances 0.000 claims description 5
- 239000008213 purified water Substances 0.000 claims description 5
- 229910052711 selenium Inorganic materials 0.000 claims description 5
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims description 4
- 238000004090 dissolution Methods 0.000 claims description 4
- 229910052748 manganese Inorganic materials 0.000 claims description 4
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 claims description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 3
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 claims description 3
- 229910052796 boron Inorganic materials 0.000 claims description 3
- 229910052732 germanium Inorganic materials 0.000 claims description 3
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 claims description 3
- 229930182817 methionine Natural products 0.000 claims description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 3
- 230000002335 preservative effect Effects 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 229910052719 titanium Inorganic materials 0.000 claims description 3
- 239000004475 Arginine Substances 0.000 claims description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 2
- 239000004472 Lysine Substances 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 2
- 235000018417 cysteine Nutrition 0.000 claims description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 2
- 238000011534 incubation Methods 0.000 claims 1
- 239000002131 composite material Substances 0.000 abstract description 12
- 230000000694 effects Effects 0.000 description 17
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 14
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 14
- 229960001031 glucose Drugs 0.000 description 14
- 235000002639 sodium chloride Nutrition 0.000 description 12
- 230000009102 absorption Effects 0.000 description 10
- 238000010521 absorption reaction Methods 0.000 description 10
- 150000003735 xanthophylls Chemical class 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 8
- 239000001656 lutein Substances 0.000 description 8
- 235000012680 lutein Nutrition 0.000 description 8
- 229960005375 lutein Drugs 0.000 description 8
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 8
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 8
- 235000008210 xanthophylls Nutrition 0.000 description 8
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 240000006024 Lactobacillus plantarum Species 0.000 description 7
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 7
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 description 7
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 description 7
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 description 7
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 7
- 229940072205 lactobacillus plantarum Drugs 0.000 description 7
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 7
- 235000015097 nutrients Nutrition 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 235000010930 zeaxanthin Nutrition 0.000 description 7
- 229940043269 zeaxanthin Drugs 0.000 description 7
- 239000001775 zeaxanthin Substances 0.000 description 7
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 229920001817 Agar Polymers 0.000 description 6
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 6
- 239000008272 agar Substances 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 229920002674 hyaluronan Polymers 0.000 description 6
- 229960003160 hyaluronic acid Drugs 0.000 description 6
- 239000011777 magnesium Substances 0.000 description 6
- 229910052698 phosphorus Inorganic materials 0.000 description 6
- 239000011574 phosphorus Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 6
- 235000019155 vitamin A Nutrition 0.000 description 6
- 239000011719 vitamin A Substances 0.000 description 6
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 5
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 5
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 5
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 5
- 229930003316 Vitamin D Natural products 0.000 description 5
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 5
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 5
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 230000003078 antioxidant effect Effects 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000036737 immune function Effects 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 229910052749 magnesium Inorganic materials 0.000 description 5
- 239000011591 potassium Substances 0.000 description 5
- 229910052700 potassium Inorganic materials 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 235000019166 vitamin D Nutrition 0.000 description 5
- 239000011710 vitamin D Substances 0.000 description 5
- 150000003710 vitamin D derivatives Chemical class 0.000 description 5
- 229940045997 vitamin a Drugs 0.000 description 5
- 229940046008 vitamin d Drugs 0.000 description 5
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 241000972773 Aulopiformes Species 0.000 description 4
- 241000193830 Bacillus <bacterium> Species 0.000 description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 4
- 244000078534 Vaccinium myrtillus Species 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 235000021466 carotenoid Nutrition 0.000 description 4
- 239000013522 chelant Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 235000015872 dietary supplement Nutrition 0.000 description 4
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 229940096421 milk thistle extract Drugs 0.000 description 4
- 235000020727 milk thistle extract Nutrition 0.000 description 4
- 229960003512 nicotinic acid Drugs 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 230000001850 reproductive effect Effects 0.000 description 4
- 210000001525 retina Anatomy 0.000 description 4
- 235000019515 salmon Nutrition 0.000 description 4
- 239000001632 sodium acetate Substances 0.000 description 4
- 235000017281 sodium acetate Nutrition 0.000 description 4
- 239000002689 soil Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 239000011573 trace mineral Substances 0.000 description 4
- 235000013619 trace mineral Nutrition 0.000 description 4
- 238000003911 water pollution Methods 0.000 description 4
- 239000011701 zinc Substances 0.000 description 4
- 229910052725 zinc Inorganic materials 0.000 description 4
- 241001474374 Blennius Species 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 235000010841 Silybum marianum Nutrition 0.000 description 3
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 3
- 229930003451 Vitamin B1 Natural products 0.000 description 3
- 229930003537 Vitamin B3 Natural products 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 150000001747 carotenoids Chemical class 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 235000019688 fish Nutrition 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000013028 medium composition Substances 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 3
- 238000002161 passivation Methods 0.000 description 3
- 239000006041 probiotic Substances 0.000 description 3
- 235000018291 probiotics Nutrition 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 229960003495 thiamine Drugs 0.000 description 3
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 3
- 235000010374 vitamin B1 Nutrition 0.000 description 3
- 239000011691 vitamin B1 Substances 0.000 description 3
- 235000019160 vitamin B3 Nutrition 0.000 description 3
- 239000011708 vitamin B3 Substances 0.000 description 3
- 235000019158 vitamin B6 Nutrition 0.000 description 3
- 239000011726 vitamin B6 Substances 0.000 description 3
- 229940011671 vitamin b6 Drugs 0.000 description 3
- 241000251468 Actinopterygii Species 0.000 description 2
- 241000193744 Bacillus amyloliquefaciens Species 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 2
- 235000012905 Brassica oleracea var viridis Nutrition 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- -1 Hexafluorophosphate Chemical compound 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000005374 Poisoning Diseases 0.000 description 2
- 241000320380 Silybum Species 0.000 description 2
- 241001148470 aerobic bacillus Species 0.000 description 2
- 238000003915 air pollution Methods 0.000 description 2
- NBZANZVJRKXVBH-ITUXNECMSA-N all-trans-alpha-cryptoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CCCC2(C)C)C NBZANZVJRKXVBH-ITUXNECMSA-N 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 235000021028 berry Nutrition 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000009920 chelation Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 239000002361 compost Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 235000013325 dietary fiber Nutrition 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 210000002969 egg yolk Anatomy 0.000 description 2
- 235000013345 egg yolk Nutrition 0.000 description 2
- 235000020774 essential nutrients Nutrition 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 230000005965 immune activity Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000010871 livestock manure Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 231100000572 poisoning Toxicity 0.000 description 2
- 230000000607 poisoning effect Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000002207 retinal effect Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 238000003900 soil pollution Methods 0.000 description 2
- 239000012439 solid excipient Substances 0.000 description 2
- 239000002352 surface water Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 230000004393 visual impairment Effects 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- DMASLKHVQRHNES-UPOGUZCLSA-N (3R)-beta,beta-caroten-3-ol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C DMASLKHVQRHNES-UPOGUZCLSA-N 0.000 description 1
- NBZANZVJRKXVBH-DJPRRHJBSA-N (3R,6'R)-beta,epsilon-caroten-3-ol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=C[C@H]1C(C)=CCCC1(C)C NBZANZVJRKXVBH-DJPRRHJBSA-N 0.000 description 1
- AEQDJSLRWYMAQI-UHFFFAOYSA-N 2,3,9,10-tetramethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-UHFFFAOYSA-N 0.000 description 1
- LPOSZYSKJWFIQH-UHFFFAOYSA-N 2-aminoacetic acid;iron Chemical compound [Fe].NCC(O)=O LPOSZYSKJWFIQH-UHFFFAOYSA-N 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 241000193755 Bacillus cereus Species 0.000 description 1
- 241000193749 Bacillus coagulans Species 0.000 description 1
- 241000193422 Bacillus lentus Species 0.000 description 1
- 241000194108 Bacillus licheniformis Species 0.000 description 1
- 241001249117 Bacillus mojavensis Species 0.000 description 1
- 241001226430 Bacillus polyfermenticus Species 0.000 description 1
- 241000194103 Bacillus pumilus Species 0.000 description 1
- 241001249119 Bacillus vallismortis Species 0.000 description 1
- 241000219198 Brassica Species 0.000 description 1
- 235000003351 Brassica cretica Nutrition 0.000 description 1
- 240000002791 Brassica napus Species 0.000 description 1
- 235000011293 Brassica napus Nutrition 0.000 description 1
- 240000007124 Brassica oleracea Species 0.000 description 1
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 1
- 240000004073 Brassica oleracea var. viridis Species 0.000 description 1
- 235000000540 Brassica rapa subsp rapa Nutrition 0.000 description 1
- 235000003343 Brassica rupestris Nutrition 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 241000132536 Cirsium Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010061452 Complication of pregnancy Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 244000124209 Crocus sativus Species 0.000 description 1
- 235000015655 Crocus sativus Nutrition 0.000 description 1
- 208000035976 Developmental Disabilities Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000019395 Lactation disease Diseases 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 240000001929 Lactobacillus brevis Species 0.000 description 1
- 235000013957 Lactobacillus brevis Nutrition 0.000 description 1
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 1
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 235000013958 Lactobacillus casei Nutrition 0.000 description 1
- 241000218492 Lactobacillus crispatus Species 0.000 description 1
- 241001134659 Lactobacillus curvatus Species 0.000 description 1
- 241000186673 Lactobacillus delbrueckii Species 0.000 description 1
- 241001147746 Lactobacillus delbrueckii subsp. lactis Species 0.000 description 1
- 241000186840 Lactobacillus fermentum Species 0.000 description 1
- 240000002605 Lactobacillus helveticus Species 0.000 description 1
- 235000013967 Lactobacillus helveticus Nutrition 0.000 description 1
- 241000186605 Lactobacillus paracasei Species 0.000 description 1
- 241001448603 Lactobacillus perolens Species 0.000 description 1
- 241000186604 Lactobacillus reuteri Species 0.000 description 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 1
- 241000186869 Lactobacillus salivarius Species 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 241000178960 Paenibacillus macerans Species 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 229910004298 SiO 2 Inorganic materials 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 244000272459 Silybum marianum Species 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- NBZANZVJRKXVBH-GYDPHNCVSA-N alpha-Cryptoxanthin Natural products O[C@H]1CC(C)(C)C(/C=C/C(=C\C=C\C(=C/C=C/C=C(\C=C\C=C(/C=C/[C@H]2C(C)=CCCC2(C)C)\C)/C)\C)/C)=C(C)C1 NBZANZVJRKXVBH-GYDPHNCVSA-N 0.000 description 1
- 235000005861 alpha-cryptoxanthin Nutrition 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000947 anti-immunosuppressive effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 229940054340 bacillus coagulans Drugs 0.000 description 1
- 229940104704 bacillus polyfermenticus Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 235000002360 beta-cryptoxanthin Nutrition 0.000 description 1
- 239000011774 beta-cryptoxanthin Substances 0.000 description 1
- DMASLKHVQRHNES-ITUXNECMSA-N beta-cryptoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CCCC2(C)C DMASLKHVQRHNES-ITUXNECMSA-N 0.000 description 1
- 229940102480 bilberry extract Drugs 0.000 description 1
- 235000019209 bilberry extract Nutrition 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940077731 carbohydrate nutrients Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 210000000078 claw Anatomy 0.000 description 1
- 239000002734 clay mineral Substances 0.000 description 1
- 230000003749 cleanliness Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 229940111685 dibasic potassium phosphate Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000019621 digestibility Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- AIUDWMLXCFRVDR-UHFFFAOYSA-N dimethyl 2-(3-ethyl-3-methylpentyl)propanedioate Chemical compound CCC(C)(CC)CCC(C(=O)OC)C(=O)OC AIUDWMLXCFRVDR-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 150000002118 epoxides Chemical class 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 208000001130 gallstones Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003673 groundwater Substances 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 229940004208 lactobacillus bulgaricus Drugs 0.000 description 1
- 229940017800 lactobacillus casei Drugs 0.000 description 1
- 229940012969 lactobacillus fermentum Drugs 0.000 description 1
- 229940054346 lactobacillus helveticus Drugs 0.000 description 1
- 229940001882 lactobacillus reuteri Drugs 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 150000002658 luteins Chemical class 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 230000001483 mobilizing effect Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 235000010460 mustard Nutrition 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 235000019645 odor Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 125000001741 organic sulfur group Chemical group 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 108091008695 photoreceptors Proteins 0.000 description 1
- 230000029553 photosynthesis Effects 0.000 description 1
- 238000010672 photosynthesis Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000008635 plant growth Effects 0.000 description 1
- 238000004161 plant tissue culture Methods 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 208000012113 pregnancy disease Diseases 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 208000007442 rickets Diseases 0.000 description 1
- 239000004248 saffron Substances 0.000 description 1
- 235000013974 saffron Nutrition 0.000 description 1
- 208000037921 secondary disease Diseases 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 231100001055 skeletal defect Toxicity 0.000 description 1
- 230000009645 skeletal growth Effects 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 229960004249 sodium acetate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 229960002668 sodium chloride Drugs 0.000 description 1
- 239000000176 sodium gluconate Substances 0.000 description 1
- 235000012207 sodium gluconate Nutrition 0.000 description 1
- 229940005574 sodium gluconate Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019195 vitamin supplement Nutrition 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000001052 yellow pigment Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
- A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/40—Mineral licks, e.g. salt blocks
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/20—Inorganic substances, e.g. oligoelements
- A23K20/24—Compounds of alkaline earth metals, e.g. magnesium
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/20—Inorganic substances, e.g. oligoelements
- A23K20/28—Silicates, e.g. perlites, zeolites or bentonites
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/20—Inorganic substances, e.g. oligoelements
- A23K20/30—Oligoelements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K40/00—Shaping or working-up of animal feeding-stuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/31—Foods, ingredients or supplements having a functional effect on health having an effect on comfort perception and well-being
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Animal Husbandry (AREA)
- Microbiology (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Physiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Fodder In General (AREA)
Abstract
본 발명은 배지에 유산균 및 고초균을 접종하여 복합균주 배양액을 배양하는 단계와; 상기 복합균주 배양액을 복합균주와 배양 상등액으로 분리한 후 상기 배양 상등액을 별도로 선별하는 단계와; 상기 배양 상등액에 무기태미네랄을 용해시켜 무기태미네랄 용해액을 조성하는 단계와; 상기 배양 상등액에 아미노산을 용해시켜 아미노산 용해액을 조성하는 단계와; 상기 무기태미네랄 용해액과 아미노산 용해액을 혼합하여 킬레이트 반응을 통해 유기태미네랄 용액으로 조성하는 단계와; 상기 유기태미네랄 용액을 동결건조시키는 단계;를 포함하는 것을 특징으로 하는 반려동물용 사료첨가제의 제조방법을 개시한다. The present invention discloses a method for manufacturing a pet feed additive, comprising: a step of culturing a composite strain culture by inoculating a medium with lactic acid bacteria and Bacillus subtilis; a step of separating the composite strain culture into a composite strain and a culture supernatant, and then separately selecting the culture supernatant; a step of dissolving an inorganic mineral in the culture supernatant to form an inorganic mineral solution; a step of dissolving an amino acid in the culture supernatant to form an amino acid solution; a step of mixing the inorganic mineral solution and the amino acid solution to form an organic mineral solution through a chelating reaction; and a step of freeze-drying the organic mineral solution.
Description
본 발명은 배지에 유산균 및 고초균을 접종하여 복합균주 배양액을 배양하는 단계와; 상기 복합균주 배양액을 복합균주와 배양 상등액으로 분리한 후 상기 배양 상등액을 별도로 선별하는 단계와; 상기 배양 상등액에 무기태미네랄을 용해시켜 무기태미네랄 용해액을 조성하는 단계와; 상기 배양 상등액에 아미노산을 용해시켜 아미노산 용해액을 조성하는 단계와; 상기 무기태미네랄 용해액과 아미노산 용해액을 혼합하여 킬레이트 반응을 통해 유기태미네랄 용액으로 조성하는 단계와; 상기 유기태미네랄 용액을 동결건조시키는 단계;를 포함하는 것을 특징으로 하는 반려동물용 사료첨가제의 제조방법에 관한 것이다. The present invention relates to a method for producing a pet feed additive, comprising: a step of culturing a composite strain culture by inoculating a medium with lactic acid bacteria and Bacillus subtilis; a step of separating the composite strain culture into a composite strain and a culture supernatant, and then separately selecting the culture supernatant; a step of dissolving an inorganic mineral in the culture supernatant to form an inorganic mineral solution; a step of dissolving an amino acid in the culture supernatant to form an amino acid solution; a step of mixing the inorganic mineral solution and the amino acid solution to form an organic mineral solution through a chelating reaction; and a step of freeze-drying the organic mineral solution.
현대 사회는 고령화의 가속화와 독신가구의 증가와 같은 인구 구조의 변화가 꾸준히 이루어지면서, 반려동물을 단순한 애완동물이 아닌, 하나의 가족 구성원 또는 삶의 동반자로 인식하는 사람들의 수가 점점 증가하고 있다.As modern society continues to experience changes in its population structure, such as the acceleration of aging and the increase in single-person households, the number of people who perceive their pets as family members or life companions rather than simply pets is increasing.
반려동물은 가족의 일원으로써 보호받으면서 사람들과 더불어 살아가고 있지만, 사람들이 겪고 있는 대기나 수질 오염 등과 같은 오염된 자연환경이나 가공식품 및 스트레스에도 함께 노출되기 때문에, 반려동물들도 사람에게 흔히 발생하는 피부질환, 호흡기 질환, 소화기 장애 등과 같은 여러 가지 질병에 취약할 수 밖에 없다. 게다가 반려동물은 주로 실내 공간에서 생활하기 때문에 운동량이 적어 비만이 우려되고 이로 인한 2차적인 질병의 발생 가능성이 높다.Pets live with people and are protected as family members, but they are also exposed to polluted natural environments such as air and water pollution, processed foods, and stress that people experience, so they are vulnerable to various diseases such as skin diseases, respiratory diseases, and digestive disorders that are common to people. In addition, pets mainly live indoors, so they do not get much exercise, which raises concerns about obesity and increases the possibility of secondary diseases.
반려동물의 건강에 대한 과거의 사람들 인식에서는, 반려동물이 각종 질환에 걸려 증상을 보이면 동물 병원에 데리고 가서 치료를 받게 하거나 약을 처방받는 등의, 대부분 사후 치료가 행해지는 소극적인 케어로 족하였다.In the past, people's perception of pet health was such that when pets showed symptoms of various diseases, they were mostly treated by taking them to a veterinary hospital for treatment or prescription medication, and passive care was sufficient.
그러나, 최근에는 반려동물의 건강에 대한 보호자들의 생각이, 인간의 건강관리와 마찬가지로, 보다 근본적인 면역 체계를 향상시킴으로써 각종 질환과 감염 등에 미리 대비할 수 있기 위한 방법에 포커스되고 있다.However, recently, the guardians' thoughts on the health of their pets are focusing on ways to prepare for various diseases and infections in advance by improving the fundamental immune system, similar to human health management.
따라서, 반려동물이 보다 건강하게 삶을 영위할 수 있기 위한, 다양한 반려동물용 사료, 영양제, 의약품 등에 대한 기술 개발이 활발히 진행되고 있고, 국내 반려동물 관련 시장 규모는 해마다 급격한 성장 추세를 나타내고 있다. 예를 들면, 반려동물용 사료 조성물의 필수 영양소를 골고루 배합하거나, 특정 영양소나 생리활성 성분을 보충하기 위해 고단백 또는 비타민과 미네랄 등을 고함량으로 배합하기도 하고, 사료 이외에 추가적으로 면역 증진을 위한 반려동물용 영양제를 출시하기도 한다. 또는 적절한 사료량과 영양제를 효과적으로 급식할 수 있는 반려동물용 급식시스템과 같은 프로그램이 개발되기도 한다.Accordingly, in order for companion animals to live healthier lives, active development of technologies for various pet foods, nutritional supplements, and medicines is underway, and the domestic pet-related market size is showing a rapid growth trend every year. For example, essential nutrients in pet food compositions are evenly mixed, or high-protein or vitamins and minerals are mixed in high amounts to supplement specific nutrients or physiologically active ingredients, and in addition to feed, nutritional supplements for companion animals are released to enhance immunity. Or, programs such as feeding systems for companion animals that can effectively feed appropriate amounts of feed and nutritional supplements are developed.
이러한 사료 첨가제의 대표적인 예로써 사용되었던 항생제는 과다 사용에 관한 문제점이 지속적으로 제기되고 있으며, 특히 영국과 미국 등 선진국에는 이러한 문제에 대처할 위원회를 설치하였고, EU와 WHO는 1997년 이후 점차적으로 인체에 사용되고 있는 항생제, 항미생물, 성장촉진제(AMGP) 및 호르몬제의 사용도 엄격히 금지하고 있다. Antibiotics, which have been used as a representative example of such feed additives, have been continuously raising issues regarding their overuse, and in particular, developed countries such as the UK and the US have established committees to deal with such issues, and the EU and WHO have also been strictly prohibiting the use of antibiotics, antimicrobials, growth promoters (AMGPs) and hormones used in humans since 1997.
이에 따라, 국내에서도 항생제를 대체할 새로운 제품이나 사료첨가용 생균제의 개발이 요구되고 있으며, 항생제 대체제로 효소제, 생균제 및 식물성 생리 활성물질에 대한 관심이 증대되고 있다. Accordingly, there is a growing demand for the development of new products to replace antibiotics or probiotics for feed additives in Korea, and interest in enzymes, probiotics, and plant-based bioactive substances as alternatives to antibiotics is increasing.
하지만, 국내 항생제 대체 보조사료 및 사료 첨가제의 경우 단순한 액상 형태의 생균제가 대부분이며, 연구개발에서도 제형보다는 미생물 찾기에 초점이 맞추어져 있는 실정이다. However, in the case of domestic antibiotic substitutes and feed additives, most are simple liquid probiotics, and research and development is focused on finding microorganisms rather than formulations.
한편, 일반적으로 반려동물용 사료에는 여러가지 영양소들이 함유되어 있으며, 대표적으로 아연(Zn), 크롬(Cr), 마그네슘(Mg), 철(Fe) 등의 미네랄을 들 수 있다. Meanwhile, pet food generally contains various nutrients, and representative minerals include zinc (Zn), chromium (Cr), magnesium (Mg), and iron (Fe).
상기의 미네랄은 비록 동물체 조직 내에 존재하는 비율도 작고 과량으로 존재하면 중독을 일으키는 중금속으로서도 작용하지만 생체 내에서는 반드시 필요한 필수 미량 광물질로 작용하기 때문에 매우 중요하다.Although the above minerals exist in small proportions in animal tissues and act as heavy metals that cause poisoning when present in excessive amounts, they are very important because they act as essential trace minerals that are absolutely necessary in the body.
그런데, 상기 미네랄이 무기태인 경우에는 체내 흡수율이 매우 낮기 때문에 그 사용량이 매우 높아짐으로써 동물에 중독증상을 초래할 수 있을 뿐만 아니라 흡수가 되지 않는 미네랄은 체외로 배설되어 토양 및 수질오염원이 될 수 있다. However, if the above minerals are inorganic, their absorption rate in the body is very low, so if the amount used is very high, it can cause poisoning symptoms in animals, and minerals that are not absorbed can be excreted from the body and become a source of soil and water pollution.
또한, 사료첨가제에 포함되는 무기태 광물질은 생체 이용률이 불과 20~30%이하이고, 나머지는 분뇨로 방출되어 버리기 때문에 선진국에서는 이와 같은 무기태 광물질의 사용에 대한 규제를 강화하고 있으며, 우리나라도 동일하게 제한되고 있는 실정이다. 특히, 2020년 3월 25일 기준으로 퇴비 부숙도 의무화가 시행되면서 퇴비 내 구리와 아연의 함량은 각각 500ppm 및 1200ppm 이하로 관리되어야 하므로 이에 따른 사료 내 무기태 광물질의 관리가 시급한 실정에 있다. In addition, since the bioavailability of inorganic minerals included in feed additives is only 20-30% or less, and the remainder is released as manure, developed countries are strengthening regulations on the use of such inorganic minerals, and Korea is also restricting them. In particular, as of March 25, 2020, the compost maturity requirement has been implemented, and the copper and zinc contents in compost must be managed below 500 ppm and 1,200 ppm, respectively, so the management of inorganic minerals in feed is urgent.
본 발명은 상기와 같은 문제점을 해결하기 위하여 발명된 것으로, 체내 흡수율을 높여 성장율을 증가시킬 수 있으며, 면역기능 개선효과를 기대할 수 있고, 체외로 배출되는 미네랄의 양을 줄일 수 있는 반려동물용 사료첨가제의 제조방법을 제공하는데 그 목적이 있다. The present invention was invented to solve the above problems, and the purpose of the present invention is to provide a method for manufacturing a pet feed additive that can increase the growth rate by increasing the absorption rate in the body, can expect an effect of improving immune function, and can reduce the amount of minerals excreted from the body.
상기와 같은 목적을 위하여 본 발명은 정제수 94~98중량%와, 글루코즈(Glucose) 1~3중량%와, 효모추출물(Yeast extract) 0.5~2중량%와, 염화나트륨(NaCl) 0.1~0.5중량%와, 인산일수소칼륨(K2HPO4) 0.1~0.5중량%로 이루어지는 배지를 120~125℃로 15분간 멸균을 실시한 다음, 상기 배지에 유산균 및 고초균을 접종한 후, 온도 30~37℃로, 공기 주입량 0.2~0.4vvm, 회전 속도 50~200rpm으로 24~36시간 배양하되, 상기 유산균 및 고초균의 증식을 촉진시킬 수 있도록 상기 배지에 해수 유래 미네랄 농축수, 유황의 수분산액 또는 일라이트의 수분산액 중 하나 또는 그 이상을 첨가하여 복합균주 배양액을 배양하는 복합균주 배양액 배양단계와; 상기 복합균주 배양액을 복합균주와 배양 상등액으로 분리한 후 상기 배양 상등액을 별도로 선별하는 배양 상등액 준비단계와; 상기 배양 상등액에 무기태미네랄을 용해시켜 무기태미네랄 용해액을 조성하는 무기태미네랄 용해액 조성단계와; 상기 배양 상등액에 아미노산을 용해시켜 아미노산 용해액을 조성하는 아미노산 용해액 조성단계와; 상기 무기태미네랄 용해액과 아미노산 용해액을 혼합하여 킬레이트 반응을 통해 유기태미네랄 용액으로 조성하는 유기태미네랄 용액 조성단계와; 상기 유기태미네랄 용액을 동결건조시키는 동결건조단계;를 포함하는 것을 특징으로 한다.
또한, 본 발명은 포도당 30~50중량%와, 효모배양액 20~40중량%와, 옥수수전분 25~30중량%와, 글루타민산 1~5중량%로 이루어지는 배지를 120~125℃로 15분간 멸균을 실시한 다음, 상기 배지에 유산균 및 고초균을 접종한 후, 온도 30~37℃로, 공기 주입량 0.2~0.4vvm, 회전 속도 50~200rpm으로 24~36시간 배양하되, 상기 유산균 및 고초균의 증식을 촉진시킬 수 있도록 상기 배지에 해수 유래 미네랄 농축수, 유황의 수분산액 또는 일라이트의 수분산액 중 하나 또는 그 이상을 첨가하여 복합균주 배양액을 배양하는 복합균주 배양액 배양단계와; 상기 복합균주 배양액을 복합균주와 배양 상등액으로 분리한 후 상기 배양 상등액을 별도로 선별하는 배양 상등액 준비단계와; 상기 배양 상등액에 무기태미네랄을 용해시켜 무기태미네랄 용해액을 조성하는 무기태미네랄 용해액 조성단계와; 상기 배양 상등액에 아미노산을 용해시켜 아미노산 용해액을 조성하는 아미노산 용해액 조성단계와; 상기 무기태미네랄 용해액과 아미노산 용해액을 혼합하여 킬레이트 반응을 통해 유기태미네랄 용액으로 조성하는 유기태미네랄 용액 조성단계와; 상기 유기태미네랄 용액을 동결건조시키는 동결건조단계;를 포함하는 것을 특징으로 한다. For the above purpose, the present invention comprises a medium comprising 94 to 98 wt% of purified water, 1 to 3 wt% of glucose, 0.5 to 2 wt% of yeast extract, 0.1 to 0.5 wt% of sodium chloride (NaCl), and 0.1 to 0.5 wt% of potassium hydrogen phosphate ( K2HPO4 ), which is sterilized at 120 to 125°C for 15 minutes, and then lactic acid bacteria and Bacillus subtilis are inoculated into the medium, and then cultured for 24 to 36 hours at a temperature of 30 to 37°C, an air injection amount of 0.2 to 0.4 vvm, and a rotation speed of 50 to 200 rpm, and one or more of a seawater-derived mineral concentrate, an aqueous sulfur dispersion, or an aqueous illite dispersion is added to the medium so as to promote the growth of the lactic acid bacteria and Bacillus subtilis, thereby culturing a complex strain culture. It is characterized by including a culturing step; a culture supernatant preparation step of separating the composite strain culture into a composite strain and a culture supernatant, and then separately selecting the culture supernatant; an inorganic mineral solution composition step of dissolving inorganic minerals in the culture supernatant to create an inorganic mineral solution; an amino acid solution composition step of dissolving amino acids in the culture supernatant to create an amino acid solution; an organic mineral solution composition step of mixing the inorganic mineral solution and the amino acid solution through a chelating reaction to create an organic mineral solution; and a freeze-drying step of freeze-drying the organic mineral solution.
In addition, the present invention comprises a medium comprising 30 to 50 wt% of glucose, 20 to 40 wt% of yeast culture, 25 to 30 wt% of corn starch, and 1 to 5 wt% of glutamic acid, sterilizing the medium at 120 to 125°C for 15 minutes, inoculating the medium with lactic acid bacteria and Bacillus subtilis, and culturing the medium at a temperature of 30 to 37°C, an air injection amount of 0.2 to 0.4 vvm, and a rotation speed of 50 to 200 rpm for 24 to 36 hours, wherein one or more of a seawater-derived mineral concentrate, an aqueous sulfur dispersion, or an aqueous illite dispersion is added to the medium so as to promote the growth of the lactic acid bacteria and Bacillus subtilis, thereby culturing the complex strain culture, the complex strain culture culturing step; a culture supernatant preparation step of separating the complex strain culture into a complex strain and a culture supernatant, and then separately selecting the culture supernatant; It is characterized by including an inorganic mineral solution composition step of dissolving inorganic minerals in the culture supernatant to create an inorganic mineral solution; an amino acid solution composition step of dissolving amino acids in the culture supernatant to create an amino acid solution; an organic mineral solution composition step of mixing the inorganic mineral solution and the amino acid solution to create an organic mineral solution through a chelating reaction; and a freeze-drying step of freeze-drying the organic mineral solution.
삭제delete
또한, 본 발명에서 상기 무기태미네랄 용해액 조성단계(S30)는 상기 배양 상등액 100중량부에 대하여 크롬(Cr), 아연(Zn), 철(Fe), 구리(Cu), 셀레늄(Se), 망간(Mn), 붕소(B), 티타늄(Ti), 게르마늄(Ge), 칼슘(Ca)으로 이루어진 군 중에서 선택된 어느 하나의 무기태 미네랄 1~10중량부를 용해시켜 무기태미네랄 용해액을 조성하며, 상기 배양 상등액의 pH를 조절하여 상기 무기태미네랄의 용해를 촉진시킬 수 있도록 유기산이 더 첨가되는 것을 특징으로 한다. In addition, in the present invention, the step (S30) of forming an inorganic mineral solution is characterized in that the step comprises forming an inorganic mineral solution by dissolving 1 to 10 parts by weight of any one inorganic mineral selected from the group consisting of chromium (Cr), zinc (Zn), iron (Fe), copper (Cu), selenium (Se), manganese (Mn), boron (B), titanium (Ti), germanium (Ge), and calcium (Ca) with respect to 100 parts by weight of the culture supernatant, and an organic acid is further added to adjust the pH of the culture supernatant to promote the dissolution of the inorganic mineral.
또한, 본 발명에서 상기 아미노산 용해액 조성단계에서, 상기 아미노산은 글리신이며, 상기 글리신은 배양 상등액 100중량부에 대하여 0.1~10중량부가 첨가되고, 상기 무기태미네랄 용해액과의 킬레이트 반응을 촉진시킬 수 있도록 글루탐산이 더 첨가되는 것을 특징으로 한다. In addition, in the amino acid solution composition step of the present invention, the amino acid is glycine, and 0.1 to 10 parts by weight of glycine is added per 100 parts by weight of the culture supernatant, and glutamic acid is further added to promote a chelating reaction with the inorganic mineral solution.
또한, 본 발명에 따른 상기 아미노산 용해액을 조성하는 단계에서, 상기 아미노산은 글리신이며, 상기 글리신은 배양 상등액 100중량부에 대하여 0.1~10중량부가 참가되고, 상기 무기태미네랄 용해액과의 킬레이트 반응을 촉진시킬 수 있도록 글루탐산이 더 첨가되는 것을 특징으로 한다. In addition, in the step of forming the amino acid solution according to the present invention, the amino acid is glycine, and 0.1 to 10 parts by weight of the glycine is added based on 100 parts by weight of the culture supernatant, and glutamic acid is further added to promote a chelating reaction with the inorganic mineral solution.
또한, 본 발명은 상기 동결건조단계에서 제조된 유기태미네랄 분말과, 물과, 부형제와, 보존제 및 기능성 첨가제를 혼합, 교반시키는 단계;를 포함하는 것을 특징으로 한다. In addition, the present invention is characterized by including a step of mixing and stirring the organic mineral powder manufactured in the freeze-drying step, water, excipients, preservatives, and functional additives.
상기와 같이 이루어지는 본 발명의 바람직한 실시예에 따라 제조되는 반려동물용 사료첨가제는 미네랄과 아미노산의 킬레이트 결합을 통해 체내 미네랄 흡수율이 향상되어 성장율을 증가시킬 수 있으며, 면역기능 개선효과를 기대할 수 있고, 체외로 배출되는 미네랄의 양을 줄일 수 있는 현저한 효과가 있다. The pet feed additive manufactured according to a preferred embodiment of the present invention, which is made as described above, can increase the growth rate by improving the absorption rate of minerals in the body through the chelate bond of minerals and amino acids, can expect the effect of improving immune function, and has a remarkable effect of reducing the amount of minerals excreted from the body.
도 1은 본 발명에 따른 반려동물용 사료첨가제의 제조공정도.Figure 1 is a manufacturing process diagram of a pet feed additive according to the present invention.
이하, 첨부된 도면을 참조하면서 본 발명에 따른 반려동물용 사료첨가제의 제조방법에 대하여 더욱 상세히 설명하도록 한다. Hereinafter, a method for manufacturing a pet feed additive according to the present invention will be described in more detail with reference to the attached drawings.
본 발명은 미네랄과 아미노산의 킬레이트 결합을 통해 체내 미네랄 흡수율이 향상되어 성장율을 증가시킬 수 있으며, 면역기능 개선효과를 기대할 수 있고, 체외로 배출되는 미네랄의 양을 줄일 수 있는 반려동물용 사료첨가제의 제조방법을 개시한다. The present invention discloses a method for manufacturing a pet feed additive that can increase the growth rate by improving the absorption rate of minerals in the body through a chelate bond between minerals and amino acids, can expect an effect of improving immune function, and can reduce the amount of minerals excreted from the body.
도 1은 본 발명의 바람직한 실시예에 따른 반려동물용 사료첨가제의 제조공정도로서, 도 1과 같이 본 발명은 복합균주 배양액 배양단계(S10)와; 배양 상등액 준비단계(S20)와; 무기태미네랄 용해액 조성단계(S30)와; 아미노산 용해액 조성단계(S40)와; 유기태미네랄 용액 조성단계(S50)와; 동결건조단계(S60);를 포함한다. FIG. 1 is a manufacturing process diagram of a pet feed additive according to a preferred embodiment of the present invention. As shown in FIG. 1, the present invention includes a step of culturing a complex strain culture solution (S10); a step of preparing a culture supernatant (S20); a step of forming an inorganic mineral solution (S30); a step of forming an amino acid solution (S40); a step of forming an organic mineral solution (S50); and a step of freeze-drying (S60).
먼저, 상기 복합균주 배양액 배양단계(10)는 배지에 유산균 및 고초균을 접종하여 복합균주 배양액을 배양하는 단계이며, 상기 배양 상등액 준비단계(S20)는 상기 복합균주 배양액을 복합균주와 배양 상등액으로 분리한 후 상기 배양 상등액을 별도로 선별하는 단계이다. First, the complex strain culture solution culturing step (10) is a step of culturing the complex strain culture solution by inoculating lactic acid bacteria and Bacillus subtilis into the medium, and the culture supernatant preparation step (S20) is a step of separating the complex strain culture solution into the complex strain and the culture supernatant, and then selecting the culture supernatant separately.
상기 배지는 유산균 및 고초균의 배양이 원활하도록 적절한 배지를 사용할 수 있다. The above medium can be used as an appropriate medium to facilitate the cultivation of lactic acid bacteria and Bacillus subtilis.
일 예로써, 상기 배지는 정제수와, 글루코즈(Glucose)와, 효모추출물(Yyeast extract)과, 염화나트륨(NaCl)과, 인산일수소칼륨(K2HPO4)으로 이루어지는 배지를 사용할 수 있다. 바람직하게는, 상기 배지는 정제수 94~98중량%와, 글루코즈(Glucose) 1~3중량%와, 효모추출물(Yeast extract) 0.5~2중량%와, 염화나트륨(NaCl) 0.1~0.5중량%와, 인산일수소칼륨(K2HPO4) 0.1~0.5중량%로 이루어질 수 있다. 여기에서, 상기 글루코즈(Glucose)가 배지 조성물 총 중량에 대하여 1중량% 미만일 경우 효소의 활성을 유도하지 못하고, 3중량%를 초과하는 경우 더 이상의 효소 활성의 증가가 일어나지 않아 비효율적이다. 상기 효모추출물(Yeastextract)이 배지 조성물 총 중량에 대하여 0.5중량% 미만일 경우 균주가 원활하게 생장할 수 없고, 2중량%를 초과하는 경우 그 이상을 사용하지 않아도 균주 생장량에 큰 영향이 없기 때문에 비효율적이다. 또한, 상기 인산일수소칼륨(K2HPO4)은 배양촉진제로서, 배지 조성물 총 중량에 대하여 0.1중량% 미만일 경우 유산균 수가 감소하여 수율이 저하될 수 있다. As an example, the medium may be a medium composed of purified water, glucose, yeast extract, sodium chloride (NaCl), and potassium hydrogen phosphate (K 2 HPO 4 ). Preferably, the medium may be composed of 94 to 98 wt% of purified water, 1 to 3 wt% of glucose, 0.5 to 2 wt% of yeast extract, 0.1 to 0.5 wt% of sodium chloride (NaCl), and 0.1 to 0.5 wt% of potassium hydrogen phosphate (K 2 HPO 4 ). Here, when the glucose is less than 1 wt% with respect to the total weight of the medium composition, enzyme activity is not induced, and when it exceeds 3 wt%, enzyme activity does not increase further, which is inefficient. If the yeast extract is less than 0.5 wt% based on the total weight of the medium composition, the strain cannot grow smoothly, and if it exceeds 2 wt%, it is inefficient because it does not have a significant effect on the strain growth amount even if it is not used more than that. In addition, the potassium hydrogen phosphate (K 2 HPO 4 ) is a culture promoter, and if it is less than 0.1 wt% based on the total weight of the medium composition, the number of lactic acid bacteria may decrease, which may lower the yield.
또한, 본 발명의 다른 실시예에 따라 상기 배지는 포도당과, 효모배양액과, 옥수수전분과, 글루타민산을 포함할 수 있다. 바람직하게는, 상기 배지는 포도당 30~50중량%와, 효모배양액 20~40중량%와, 옥수수전분 25~30중량%와, 글루타민산 1~5중량%를 포함할 수 있다. 포도당은 3일 정도면 완전 분해되어 잔류 당분을 남기지 않게 됨으로써, 배지에 필요한 영양소를 제공하면서도 배양된 균사체의 순수성을 유지하는 기능을 한다. In addition, according to another embodiment of the present invention, the medium may contain glucose, yeast culture, corn starch, and glutamic acid. Preferably, the medium may contain 30 to 50 wt% of glucose, 20 to 40 wt% of yeast culture, 25 to 30 wt% of corn starch, and 1 to 5 wt% of glutamic acid. Glucose is completely decomposed in about 3 days, leaving no residual sugar, thereby providing nutrients necessary for the medium while maintaining the purity of the cultured mycelia.
또한, 상기 배지는 효모추출물과, 무수포도당과, 소이펩톤과, 타우린과, 미네랄을 포함할 수 있으며, 또는 무수포도당과, 효모추출물과, 초산나트륨과, 제2인산칼륨(K2HPO4)을 포함할 수 있고, 또는 효모추출물과, 효모배양물과, 포도당과, 초산나트륨과, 구연산을 포함할 수 있으며, 또는 효모추출물과, 설탕과, 포도당을 포함할 수 있다. Additionally, the medium may include yeast extract, anhydrous glucose, soy peptone, taurine, and minerals, or may include anhydrous glucose, yeast extract, sodium acetate, and dibasic potassium phosphate (K 2 HPO 4 ), or may include yeast extract, yeast culture, glucose, sodium acetate, and citric acid, or may include yeast extract, sugar, and glucose.
상기 유산균은 장내로 유입된 후 장내 상피세포에 착생하게 되어 유해 미생물의 장 정착을 방지하고 항균 물질을 분비함으로써 유해 미생물의 생육을 억제하고 설사와 변비를 개선할 뿐만 아니라, 면역활성 증진, 항암작용, 혈청 콜레스테롤 저하 등의 작용을 수행한다. The above lactic acid bacteria, after entering the intestines, attach to intestinal epithelial cells, thereby preventing the colonization of harmful microorganisms in the intestines and secreting antibacterial substances, thereby suppressing the growth of harmful microorganisms and improving diarrhea and constipation, as well as enhancing immune activity, having anticancer effects, and lowering serum cholesterol.
본 발명에서 상기 배지에 접종되는 유산균은 락토바실러스 불가리스(Lactobacillus bulgaricus), 락토바실러스 엑시도필러스(Lactobacillus acidophilus), 락토바실러스 델브렉키(Lactobacillus delbrueckii), 락토바실러스 플란타럼(Lactobacillus plantarum), 락토바실러스 람노서스(Lactobacillus rhamnosus), 락토바실러스 락티스(Lactobacillus delbrueckii subsp. lactis, Latobacillus lactis), 락토바실러스 루테리(Lactobacillus reuteri), 락토바실러스 브레비스(Lactobacillus brevis), 락토바실러스 살리바리우스(Lactobacillus salivarius), 락토바실러스 카제이(Lactobacillus casei), 락토바실러스 커바투스(Lactobacillus curvatus), 락토바실러스 크리스파투스(Lactobacillus crispatus), 락토바실러스 파라카제이(Lactobacillus paracasei), 락토바실러스 퍼멘텀(Lactobacillus fermentum), 락토바실러스 페롤렌스(Lactobacillus perolens), 또는 락토바실러스 헬베티쿠스(Lactobacillus helveticus) 중에서 선택된 하나일 수 있다. In the present invention, the lactic acid bacteria inoculated into the medium are Lactobacillus bulgaricus , Lactobacillus acidophilus , Lactobacillus delbrueckii , Lactobacillus plantarum , Lactobacillus rhamnosus , Lactobacillus delbrueckii subsp. lactis, Latobacillus lactis, Lactobacillus reuteri , Lactobacillus brevis , Lactobacillus salivarius , Lactobacillus casei, Lactobacillus It can be one selected from Lactobacillus curvatus, Lactobacillus crispatus , Lactobacillus paracasei , Lactobacillus fermentum, Lactobacillus perolens, or Lactobacillus helveticus .
상기 고초균은 단백질 및 전분 분해효소 생산으로 사료이용성을 증진하며 중온 및 고온성으로 내열성이 강하다. 영양분의 흡수촉진 유기산물 생성을 통하여 사료효율을 개선하며, 스트레스 해소, 면역력 증강, 그리고 생육을 증진시킨다. 또한, 고초균은 다수의 탄수화물을 분해하여 산을 생성하며, 배지 중에 다량의 단백질을 분비한다.The above-mentioned Bacillus subtilis increases feed utilization by producing protein and starch decomposition enzymes, and has strong heat resistance due to its medium and high temperature. It improves feed efficiency by promoting the absorption of nutrients and producing organic products, and relieves stress, enhances immunity, and promotes growth. In addition, Bacillus subtilis decomposes a large number of carbohydrates to produce acid, and secretes a large amount of protein into the medium.
본 발명에서 상기 배지에 접종되는 고초균은 바실러스 아밀로리퀴파시언스(Bacillus amyloliquefaciens), 바실러스 마세란스(Bacillus macerans), 바실러스 모자벤시스(Bacillus mojavensis), 바실러스 펌밀러스(Bacillus pumilus), 바실러스 발리스모르티스(Bacillus vallismortis), 바실러스 베레젠시스(Bacillus velezensis), 바실러스 렌투스(Bacillus lentus), 바실러스 리체니포미스(Bacillus licheniformis), 바실러스 세레우스(Bacillus cereus), 바실러스 코아글란스(Bacillus coagulans) 또는 바실러스 폴리퍼멘티쿠스(Bacillus polyfermenticus) 중에서 선택된 하나일 수 있다. In the present invention, the Bacillus subtilis inoculated into the medium may be one selected from Bacillus amyloliquefaciens , Bacillus macerans, Bacillus mojavensis , Bacillus pumilus , Bacillus vallismortis , Bacillus velezensis , Bacillus lentus , Bacillus licheniformis , Bacillus cereus , Bacillus coagulans, or Bacillus polyfermenticus .
상기 복합균주 배양액을 배양할 때, 먼저 상기 배지를 120~125℃로 15분간 멸균을 실시한 다음, 상기 배지에 유산균 및 고초균을 접종한 후, 온도 30~37℃로, 공기 주입량 0.2~0.4vvm, 회전 속도 50~200rpm으로 24~36시간 배양을 진행하는 것이 바람직하다. When culturing the above complex strain culture, it is preferable to first sterilize the medium at 120 to 125°C for 15 minutes, then inoculate the medium with lactic acid bacteria and Bacillus subtilis, and then culture for 24 to 36 hours at a temperature of 30 to 37°C, an air injection amount of 0.2 to 0.4 vvm, and a rotation speed of 50 to 200 rpm.
여기에서, 상기 유산균 및 고초균의 증식을 촉진시킬 수 있도록 상기 배지에 해수 유래 미네랄 농축수, 유황의 수분산액 또는 일라이트의 수분산액이 첨가될 수 있다. Here, a seawater-derived mineral concentrate, an aqueous sulfur dispersion or an aqueous illite dispersion can be added to the medium to promote the growth of the lactic acid bacteria and Bacillus subtilis.
해수 유래 미네랄 농축수라 함은 해수(海水) 또는 천일염을 이용한 소금물을 농축하거나, 또는 해수 농축수와 천일염 소금물의 농축수를 혼합하여 미네랄 함량이 증가한 염도 30~40 %의 미네랄 농축수이다.Concentrated mineral water derived from seawater refers to concentrated mineral water with a salinity of 30-40% with increased mineral content by concentrating seawater or brine using solar salt, or by mixing concentrated seawater and concentrated sea salt.
해수는 통상 33~37 %의 염도를 가지는데 식물의 생육에 필요한 질소, 인산, 규소와 같은 영양염류를 포함하여 다양한 미네랄을 함유하고 있으나 해수에는 나트륨 성분이 과잉으로 존재하므로 나트륨을 제거하면서 해수를 농축하여 사용할 수 있으며, 이렇게 얻어진 해수 유래 미네랄 농축수는 소금의 함량은 대폭 감소하면서 반려동물에게 유용한 미네랄, 예를 들어 마그네슘, 칼륨, 칼슘 등이 고함량으로 혼합된 액상의 미네랄이 된다. 마그네슘, 칼륨, 칼슘과 같은 미네랄을 물에 첨가한 수용액은 미네랄의 물에 대한 용해성이 낮고 이로 인하여 반려동물이 섭취하여도 소량만이 흡수되어 사용 효율이 낮지만, 상기 해수 유래 미네랄 농축수는 미네랄이 석출되지 않고 과량으로 용해된 상태로 존재하므로 반려동물이 용이하게 흡수하여 미네랄의 사용 효율을 높일 수 있다.Seawater usually has a salinity of 33 to 37% and contains various minerals, including nutrients such as nitrogen, phosphorus, and silicon necessary for plant growth. However, since seawater contains an excess of sodium, the sodium can be removed to concentrate the seawater and used. The resulting seawater-derived mineral concentrate has a significantly reduced salt content and is a liquid mineral mixed with a high content of minerals useful for companion animals, such as magnesium, potassium, and calcium. Aqueous solutions containing minerals such as magnesium, potassium, and calcium have low solubility in water, and therefore, only a small amount is absorbed when consumed by companion animals, which reduces the efficiency of use. However, the above seawater-derived mineral concentrate does not have minerals precipitated but exists in an excessively dissolved state, so companion animals can easily absorb it, thereby increasing the efficiency of use of the minerals.
바람직하게는, 상기 해수는 해양심층수 (deep ocean water)를 사용하는 것이 좋다. 해양심층수는 일반적으로 수심 200m 이하의 해양에 존재하는 해수로서 태양광이 도달하지 않는 심해에서는 영양물질을 소비하는 식물플랑크톤이 없고 광합성이 일어나지 않아서 질소, 인, 규산 등의 무기영양소가 풍부하며, 수심이 깊은 곳에서 장시간 정체되어 있어서 마그네슘, 칼슘, 칼륨, 나트륨 등의 다양한 미네랄과 아연, 셀렌, 망간 등의 미량원소가 안정된 형태로 다량 존재하고 있으며, 대기나 유입수에 의한 오염이 없고 표층수에 비하여 생균수가 많지 않을 뿐만 아니라 일반세균이 오염되지 않아서 지표수나 지하수에 비해 청정도가 우수하다.Preferably, the seawater used is deep ocean water. Deep ocean water is seawater that generally exists in the ocean at a depth of 200 m or less, and since there is no phytoplankton that consumes nutrients and photosynthesis does not occur in the deep sea where sunlight does not reach, it is rich in inorganic nutrients such as nitrogen, phosphorus, and silica, and since it remains stagnant in a deep place for a long time, various minerals such as magnesium, calcium, potassium, and sodium and trace elements such as zinc, selenium, and manganese exist in a stable form in large quantities, and there is no pollution by the atmosphere or inflowing water, and the number of living bacteria is not high compared to surface water, and general bacteria are not contaminated, so it has superior cleanliness compared to surface water or groundwater.
상기 유황의 수분산액은 유황 분말이 10~20 중량% 함유된 수용액을 지칭한다. 유황은 생물체를 구성하는 필수요소로서, 특히 아미노산의 생성에 영향을 주어 단백질 합성에 필요하고, 이로 인하여 성장 발육의 향상과 육질 개선에 효과가 있으며, 면역력을 강화시켜주지만, 광물질의 무기유황이나 합성유기유황은 독성과 강산성을 나타내므로 법제유황을 사용할 수 있다. The above sulfur aqueous dispersion refers to an aqueous solution containing 10 to 20 wt% of sulfur powder. Sulfur is an essential element that constitutes a living organism, and in particular, it affects the production of amino acids and is necessary for protein synthesis, and thus is effective in improving growth and development and meat quality, and strengthens immunity. However, since inorganic sulfur or synthetic organic sulfur of mineral substances exhibits toxicity and strong acidity, legal sulfur can be used.
상기 일라이트의 수분산액은 일라이트 분말이 10~20 중량% 함유된 수용액을 지칭한다. 일라이트는 운모 점토 광물이 풍화되는 동안 칼륨, 마그네슘 등이 용탈되어 생기는 비팽창형 광물로서, 구성성분 중 60~70% 함유된 이산화규소(SiO2) 성분이 미네랄 성분의 공급과잉장애 등을 해결하며, 상기 해수 유래 미네랄 성분과 함께 유산균의 생존을 높여준다. The above-mentioned aqueous dispersion of illite refers to an aqueous solution containing 10 to 20 wt% of illite powder. Illite is a non-swelling mineral that is formed when potassium, magnesium, etc. are dissolved during the weathering of mica clay minerals. The silicon dioxide (SiO 2 ) component, which accounts for 60 to 70% of the composition, solves problems such as oversupply of mineral components, and together with the mineral components derived from seawater, increases the survival of lactic acid bacteria.
본 발명에서 상기 해수 유래 미네랄 농축수, 유황의 수분산액 또는 일라이트의 수분산액 중 하나 또는 그 이상이 첨가될 수 있으며, 상기 배지 100중량부에 대하여 전체 총량이 1~10중량부로 첨가되는 것이 좋다. 바람직하게는, 전술한 다양한 작용효과를 위하여 3종 모두가 첨가는 것이 좋다. In the present invention, one or more of the above-mentioned seawater-derived mineral concentrate, sulfur aqueous dispersion, or illite aqueous dispersion may be added, and it is preferable that the total amount is added in an amount of 1 to 10 parts by weight per 100 parts by weight of the medium. Preferably, all three types are added for the above-mentioned various effects.
상기 배양액을 균주와 배양 상등액으로 분리하는 방법은 공지된 다양한 방법을 이용할 수 있으며, 예를 들어 원심분리기에 배양액을 투입하여 균주와 배양 상등액으로 분리할 수 있다. 상기 배양 상등액은 유산균 및 고초균의 발효 배양과정에서 생성되는 대사산물로서, 전술한 유산균 및 고초균에 의한 다양한 작용효과를 제공할 수 있다. The method for separating the above culture solution into strain and culture supernatant can utilize various known methods, for example, the culture solution can be placed in a centrifuge to separate the strain and culture supernatant. The above culture supernatant is a metabolic product produced during the fermentation culture process of lactic acid bacteria and Bacillus subtilis, and can provide various functional effects by the above-mentioned lactic acid bacteria and Bacillus subtilis.
다음으로, 상기 무기태미네랄 용해액 조성단계(S20)는 상기 배양 상등액에 무기태미네랄을 용해시켜 무기태미네랄 용해액을 조성하는 단계이다.Next, the step of forming the inorganic mineral solution (S20) is a step of forming the inorganic mineral solution by dissolving inorganic minerals in the culture supernatant.
본 발명에서 상기 무기태미네랄은 크롬(Cr), 아연(Zn), 철(Fe), 구리(Cu), 셀레늄(Se), 망간(Mn), 붕소(B), 티타늄(Ti), 게르마늄(Ge), 칼슘(Ca)으로 이루어진 군 중에서 선택된 어느 하나의 미네랄일 수 있다. In the present invention, the inorganic mineral may be any one mineral selected from the group consisting of chromium (Cr), zinc (Zn), iron (Fe), copper (Cu), selenium (Se), manganese (Mn), boron (B), titanium (Ti), germanium (Ge), and calcium (Ca).
반려동물이 성장하는데 있어 전술한 크롬(Cr), 아연(Zn), 철(Fe), 구리(Cu) 등 미네랄의 적절한 공급은 반드시 필요하다. 예를 들어, 아연(Zn)은 성장에 관여하는 효소 자체의 성분이므로 결핍시 사료섭취 및 사료효율의 저하, 생식기관 발육부진 및 임신수유장애, 비정상적 골격형성, 피부병원균에 대한 저항성 약화 등의 현상을 수반한다. 또한, 철(Fe)은 체내에서 산소를 운반하는 헤모글로빈을 이루는 헴(heme)의 성분으로, 결핍 시에는 헤모글로빈의 합성이 저하되어 에너지 대사율이 떨어지고 빈혈을 유발한다. 또한, 셀레늄(selenium, Se)은 여러 가지 항산화, 항염, 항바이러스 작용에 필수적인 미량 무기질이며 항산화 물질로서, 세포막 손상을 일으키는 과산화수소와 같은 활성산소를 제거하여 조직의 노화와 변성을 막아 주거나 그 속도를 지연시키며, 면역력 강화, 혈액순환 개선에 도움을 주는 것으로 알려져 있다. 즉, 이러한 미네랄은 동물체 조직에서 차지하는 비율은 낮지만 골격을 형성하고, 체내 삼투압을 조절하며, 체액의 산-염기 평형을 유지시키고, 효소계에 활성제 또는 효소 자체의 성분으로 그 역할이 매우 다양하며 또한 중요한 것이다. An adequate supply of minerals such as chromium (Cr), zinc (Zn), iron (Fe), and copper (Cu) is essential for the growth of companion animals. For example, zinc (Zn) is a component of the enzymes involved in growth, so when it is deficient, it can lead to decreased feed intake and feed efficiency, reproductive organ developmental delay, pregnancy and lactation disorders, abnormal skeletal formation, and weakened resistance to skin pathogens. In addition, iron (Fe) is a component of heme, which forms hemoglobin, which transports oxygen in the body. When it is deficient, hemoglobin synthesis decreases, lowering the energy metabolism rate and causing anemia. In addition, selenium (Se) is a trace mineral essential for various antioxidant, anti-inflammatory, and antiviral effects, and as an antioxidant, it is known to remove active oxygen such as hydrogen peroxide that causes cell membrane damage, prevent or delay the aging and degeneration of tissues, and help strengthen immunity and improve blood circulation. That is, although these minerals occupy a small proportion in animal tissues, they play a very diverse and important role in forming the skeleton, regulating the osmotic pressure in the body, maintaining the acid-base balance of body fluids, and acting as activators in enzyme systems or as components of the enzymes themselves.
본 발명의 실시예에 따라 상기 무기태미네랄 용해액은 상기 배양 상등액 100중량부에 대하여 상기 무기태미네랄 1~10중량부를 용해시켜 조성될 수 있다. 만약 상기 무기태미네랄이 1중량부 미만으로 용해되면 함량 미달로 인해 기대하는 효과를 얻지 못할 수 있다. 또한, 상기 미네랄이 무기물 형태인 경우 체내 흡수율이 현저히 떨어지며, 흡수되지 않은 미네랄이 체외로 배설되어 토양 및 수질의 오염원이 되므로 10중량부를 초과하지 않은 것이 바람직하다. According to an embodiment of the present invention, the inorganic mineral solution may be prepared by dissolving 1 to 10 parts by weight of the inorganic mineral per 100 parts by weight of the culture supernatant. If the inorganic mineral is dissolved in less than 1 part by weight, the expected effect may not be obtained due to insufficient content. In addition, if the mineral is in an inorganic form, the absorption rate in the body is significantly reduced, and unabsorbed minerals are excreted from the body and become a source of soil and water pollution, so it is preferable that it does not exceed 10 parts by weight.
또한, 본 발명의 실시예에 따라 상기 무기태미네랄 용해액 조성단계(S20)에서, 상기 배양 상등액에 무기내미네랄을 용해시킬 때 상기 배양 상등액의 pH를 조절하여 상기 무기태미네랄의 용해를 촉진시킬 수 있도록 유기산이 더 참가될 수 있다. In addition, in the step (S20) of forming the inorganic mineral solution according to an embodiment of the present invention, an organic acid may be further added to adjust the pH of the culture supernatant when dissolving the inorganic mineral in the culture supernatant to promote the dissolution of the inorganic mineral.
유기산(organic acid)이라 함은 산성을 띠는 유기화합물의 총칭이며, 카복시기와 설폰기가 들어 있는 유기화합물이 대표적인 유기산이다. 유기산으로는 아세트산(acetic acid), 뷰티르산(butyric acid), 팔미트산(palmitic acid), 옥살산(oxalic acid), 타타르산(tartaric acid) 중에서 선택된 하나일 수 있다. Organic acid is a general term for organic compounds that are acidic, and organic compounds containing carboxyl groups and sulfonic groups are representative organic acids. The organic acid can be one selected from acetic acid, butyric acid, palmitic acid, oxalic acid, and tartaric acid.
상기 유기산은 증류수에 용해시켜 액상으로 제조된 것을 사용할 수 있다. The above organic acid can be used in a liquid form by dissolving it in distilled water.
상기 유기산은 배양 상등액 100중량부에 대하여 0.5~0.7중량부가 첨가될 수 있다. 예를 들어, 상기 무기태미네랄의 용해 과정에서 상기 배양 상등액에 무기태미네랄를 첨가 후 용해시키는 과정에서 상기 배양 상등액 100중량부에 대하여 아세트산 0.5~0.7중량부가 더 첨가되어 무기태미네랄의 용해가 보다 원활하게 이루어지도록 할 수 있다. The organic acid may be added in an amount of 0.5 to 0.7 parts by weight per 100 parts by weight of the culture supernatant. For example, in the process of dissolving the inorganic mineral, 0.5 to 0.7 parts by weight of acetic acid may be additionally added per 100 parts by weight of the culture supernatant in the process of dissolving the inorganic mineral after adding the inorganic mineral to the culture supernatant. This may enable the dissolution of the inorganic mineral to occur more smoothly.
다음으로, 상기 아미노산 용해액 조성단계(S30)는 상기 배양 상등액에 아미노산을 용해시켜 아미노산 용해액을 조성하는 단계이다. Next, the amino acid solution composition step (S30) is a step of dissolving amino acids in the culture supernatant to create an amino acid solution.
본 발명의 일실시예에 따라 상기 아미노산 용해액은 상기 배양 상등액 100중량부에 대하여 아미노산 0.1~10중량부를 용해시켜 조성될 수 있다. According to one embodiment of the present invention, the amino acid solution can be prepared by dissolving 0.1 to 10 parts by weight of amino acid per 100 parts by weight of the culture supernatant.
여기에서, 아미노산은 리신, 아르기닌, 히스티딘, 시스테인, 페닐 알라닌, 타이로신, 메티오닌, 글리신으로 이루어진 군 중에서 선택된 하나일 수 있다. Here, the amino acid can be one selected from the group consisting of lysine, arginine, histidine, cysteine, phenylalanine, tyrosine, methionine, and glycine.
바람직하게는, 상기 아미노산은 글리신일 수 있으며, 상기 아미노산 용해액 조성단계는 배양 상등액 100중량부에 대하여 글리신 0.1~10중량부가 용해되어 아미노산 용해액을 조성할 수 있다. Preferably, the amino acid may be glycine, and the amino acid solution composition step may be performed by dissolving 0.1 to 10 parts by weight of glycine per 100 parts by weight of the culture supernatant to form an amino acid solution.
또한, 본 발명의 실시예에 따라 상기 아미노산 용해액 조성단계에서 상기 글리신의 킬레이션을 돕기 위해 글루탐산이 더 첨가될 수 있다. Additionally, according to an embodiment of the present invention, glutamic acid may be further added in the amino acid solution composition step to assist in the chelation of glycine.
글루탐산은 글리신의 아미노기를 활성시키는 활성화제로서, 아미노기와 반응할 수 있는 중간체를 형성하여 결합반응을 용이하게 만들어준다. 즉, 글루탐산을 첨가함으로써 아미노기의 활성화가 향상되고, 유기태화 결합반응의 효율성을 높여주는 효과를 제공한다. Glutamic acid is an activator that activates the amino group of glycine, and forms an intermediate that can react with the amino group, facilitating the bonding reaction. That is, by adding glutamic acid, the activation of the amino group is enhanced, and the efficiency of the organic passivation bonding reaction is increased.
상기 글루탐산은 상기 배양 상등액 100중량부에 대하여 0.1~10중량부가 첨가될 수 있으며, 바람직하게는 상기 글리신과 1:1 중량비 비율로 첨가될 수 있다. The above glutamic acid may be added in an amount of 0.1 to 10 parts by weight per 100 parts by weight of the culture supernatant, and preferably may be added in a weight ratio of 1:1 with the glycine.
한편, 아미노산으로서 페닐 알라닌이 선택되는 경우 활성제로서 다이아이소프로필카보다이이미드(Diisopropylcarbodiimide, DIC)가 첨가될 수 있고, 메티오닌은 다이아이소프로필카보다이이미드(Diisopropylcarbodiimide, DIC) 또는 HATU(Hexafluorophosphate Azabenzotriazole Tetramethyl Uronium)가 첨가될 수 있다. Meanwhile, when phenylalanine is selected as an amino acid, diisopropylcarbodiimide (DIC) can be added as an activator, and when methionine is selected, diisopropylcarbodiimide (DIC) or HATU (Hexafluorophosphate Azabenzotriazole Tetramethyl Uronium) can be added.
다음으로, 상기 유기태미네랄 용액 조성단계(S40)는 상기 무기태미네랄 용해액과 아미노산 용해액을 혼합하여 킬레이트 반응을 통해 유기태미네랄 용액으로 조성하는 단계로서, 이때 상기 무기태미네랄 용해액과 아미노산 용해액은 1:1 중량비 비율로 혼합될 수 있다. Next, the organic mineral solution composition step (S40) is a step of mixing the inorganic mineral solution and the amino acid solution to form an organic mineral solution through a chelating reaction. At this time, the inorganic mineral solution and the amino acid solution can be mixed at a weight ratio of 1:1.
킬레이션(chelation)이라 함은 광물질이 리간드(Ligand)에 의해 발톱으로 잡히듯이 결합함을 나타내는 것으로, 킬레이트(chelate) 화학결합은 특수성질을 지닌 유기분자인 킬레이트제(chelating agent)가 금속원소를 돌러싸고 양면에서 마치 집게로 꽉 물고 있듯이 이종환식(異種環式) 구조결합을 한 상태를 말한다. Chelation refers to a bond in which a mineral is held by a ligand as if with claws, and a chelate chemical bond refers to a state in which a chelating agent, an organic molecule with special properties, surrounds a metal element and forms a heterocyclic structural bond as if it were holding it tightly with tweezers on both sides.
아미노산이 무기태미네랄과 킬레이션되어 유기태 미량요소로 전환되면, 표면 리간드의 결합작용으로 인해 반려동물의 미네랄 흡수율이 급격히 향상되며, 성장률, 산유량, 번식효율, 체중 개선, 면역기능 등이 개선되는 효과가 있다. 또한, 미네랄의 소화 흡수율이 높아짐에 따라 분뇨 부산물 발생을 줄일 수 있고, 소화 중 장내에서 발생되는 악취 원인물질을 억제함으로써 대기, 수질 오염을 방지할 수 있고, 토양에 광물질이 과다하게 축적되는 것을 방지할 수 있다. When amino acids are chelated with inorganic minerals and converted into organic trace elements, the mineral absorption rate of companion animals is rapidly improved due to the binding action of surface ligands, and there are effects such as improved growth rate, milk production, reproductive efficiency, weight improvement, and immune function. In addition, as the digestion and absorption rate of minerals increases, the generation of fecal by-products can be reduced, and by suppressing substances causing odors generated in the intestines during digestion, air and water pollution can be prevented, and excessive mineral accumulation in the soil can be prevented.
최근에 개시된 연구보고에 따르면, 유기태 크롬은 혈당을 낮추고, 콜레스테롤 및 체지방을 감소시키는 한편 근육질을 강화시키며(GW Evans, Int J Biosocial Med Research 11(2), 163, 1989), 돼지 사료에 유기태 크롬을 200ppb로 첨가하면 돼지의 지방질과 콜레스테롤 수준이 낮아질 뿐만 아니라 근육합성량이 증가한다고 알려져 있다(K Jacques 등, Feed Management, 44, 23, 1993). 종래의 사료 첨가제는 미네랄(예를 들어 아연)이 무기물 형태로 함유되었는데, 이러한 무기태미네랄은 소화 흡수율이 20% 이내이고, 80% 이상이 분뇨의 형태로 배출되면서 심각한 토양환경 오염을 유발하는데, 본 발명은 이러한 문제점을 해결할 수 있는 현저한 효과가 있다. According to a recently published research report, organic chromium lowers blood sugar, cholesterol and body fat, and strengthens muscle (GW Evans, Int J Biosocial Med Research 11(2), 163, 1989), and it is known that adding 200 ppb of organic chromium to pig feed not only lowers the fat and cholesterol levels of pigs but also increases muscle synthesis (K Jacques et al., Feed Management, 44, 23, 1993). Conventional feed additives contain minerals (e.g., zinc) in inorganic form, but these inorganic minerals have a digestibility of less than 20% and more than 80% are discharged in the form of manure, causing serious soil environmental pollution. The present invention has a remarkable effect in solving such problems.
다음으로, 상기 동결건조단계(S50)는 상기 유기태미네랄 용액을 동결건조시켜 분말화하는 단계이다. Next, the freeze-drying step (S50) is a step of powderizing the organic mineral solution by freeze-drying it.
동결건조는 주원료 및 부원료에 포함된 수분을 건조시키기 위한 공정으로서 상기 단계를 거쳐 제조된 반료동물용 사료첨가제는 수분을 상대적으로 적게 포함하고 있기 때문에 쉽게 상하지 않고, 오랜 유통기한을 확보할 수 있다. 또한, 이후 반려동물의 기호에 맞게 수분을 첨가하여 제공할 수 있으므로 반려동물의 다양한 기호들을 충족시킬 수 있을 것이다. Freeze-drying is a process for drying the moisture contained in the main and auxiliary materials. The semi-finished animal feed additives manufactured through the above steps contain relatively little moisture, so they do not spoil easily and can secure a long shelf life. In addition, since moisture can be added to suit the pet's preference, it can satisfy the various preferences of the pet.
예를 들어, 상기 동결건조단계는 동결건조기에서 -40~-50℃로 18~36시간 수행될 수 있다. 만약, 상기 온도 및 시간 범위 미만으로 수행되면 동결건조가 원활히 수행되지 않을 수 있고, 과다하게 초과하여 수행되는 경우 이미 동결건조가 완료될 수 있는 온도 및 시간 범위를 초과하였기 때문에 비경제적인 것일 수 있다.For example, the freeze-drying step can be performed at -40 to -50°C for 18 to 36 hours in a freeze dryer. If it is performed below the temperature and time range, the freeze-drying may not be performed smoothly, and if it is performed excessively above the temperature and time range at which the freeze-drying can be completed has already been exceeded, which may be uneconomical.
이러한 공정에 의해 조성된 본 발명의 반려동물용 사료첨가제는 유산균, 고초균 성분이 1.0x106cfu/g~3.0x1012cfu/g 로 함유되어, 면역활성증진, 항암작용효과, 스트레스 해소, 면역력 증강, 생육증진효과 등을 기대할 수 있다. The pet feed additive of the present invention, prepared by this process, contains lactic acid bacteria and Bacillus subtilis components at 1.0x10 6 cfu/g to 3.0x10 12 cfu/g, and thus can be expected to have effects such as enhanced immune activity, anticancer effects, stress relief, enhanced immunity, and growth promotion.
실시예 1. Example 1.
정제수 96중량%와, 글루코즈 2중량%와, 효모추출물(Yeast extract) 1중량%와, 염화나트륨(NaCl) 0.5중량%와, 인산일수소칼륨(K2HPO4) 0.5중량%로 이루어지는 배지를 준비하였다. A medium composed of 96 wt% purified water, 2 wt% glucose, 1 wt% yeast extract, 0.5 wt% sodium chloride (NaCl), and 0.5 wt% potassium hydrogen phosphate (K 2 HPO 4 ) was prepared.
다음으로, 상기 배지에 락토바실러스 플라타럼(Lactobacillus plantarum) 및 바실러스 아밀로리퀘파시언스(Bacillus amyloliquefaciencs)를 접종한 다음 혐기성인 락토바실러스 플라타럼과 호기성인 바실러스 아밀로리퀘파시언스를 동시 배양하기 위하여 온도 32℃, 공기 주입량 0.3vvm, 회전 속도 100 rpm으로 36시간 배양하여 락토바실러스 플란타럼(Lactobacillus plantarum) 함량이 2.5x108cfu/g이고, 바실러스 아밀로리퀘파시언스(Bacillus amyloliquefaciencs)의 함량이 2.7x109cfu/g인 복합균주 배양액을 배양하였다. 이후, 상기 복합균주 배양액을 원심분리를 통해 균주와 배양 상등액으로 분리하였다. Next, Lactobacillus plantarum and Bacillus amyloliquefaciencs were inoculated onto the medium, and then the medium was cultured at 32°C, an air injection amount of 0.3 vvm, and a rotation speed of 100 rpm for 36 hours to simultaneously culture anaerobic Lactobacillus plantarum and aerobic Bacillus amyloliquefaciencs, thereby culturing a composite strain culture having a Lactobacillus plantarum content of 2.5 x 10 8 cfu/g and a Bacillus amyloliquefaciencs content of 2.7 x 10 9 cfu/g. Thereafter, the composite strain culture was separated into strains and culture supernatant through centrifugation.
다음으로, 상기 배양 상등액 100중량부에 대하여 아연 3중량부를 첨가한 다음 혼합하여 무기태미네랄 용해액을 조성하였다. Next, 3 parts by weight of zinc was added to 100 parts by weight of the culture supernatant and then mixed to form an inorganic mineral solution.
다음으로, 상기 배양 상등액 100중량부에 대하여 글리신 2중량부를 첨가한 다음 상기 글리신의 유기태화 반응을 촉진시키기 위하여 글루탐산 2중량부를 더 첨가한 후 혼합하여 아미노산 용해액을 조성하였다. Next, 2 parts by weight of glycine was added to 100 parts by weight of the culture supernatant, and then 2 parts by weight of glutamic acid was further added to promote the organic passivation reaction of the glycine, and then mixed to form an amino acid solution.
다음으로, 상기 무기태미네랄 용해액과 아미노산 용해액을 1:1 중량비 비율로 혼합하여 유기태미네랄 용액을 조성한 다음, 조성된 유기태미네랄 용액을 동결건조기에 투입하여 -50℃로 24시간 동결건조시켜 본 발명의 실시예에 따른 반려동물용 사료첨가제(글리신 유기태화 아연 분말)를 조성하였다. Next, the inorganic mineral solution and the amino acid solution were mixed in a weight ratio of 1:1 to prepare an organic mineral solution, and then the prepared organic mineral solution was placed in a freeze dryer and freeze-dried at -50°C for 24 hours to prepare a pet feed additive (organo-passivated zinc powder with glycine) according to an embodiment of the present invention.
다음으로, 본 발명은 상기 유기태미네랄 용액을 동결건조시켜 제조된 유기태미네랄 분말과, 물과, 부형제와, 보존제 및 기능성 첨가제를 혼합, 교반시켜 형상화하는 성형단계(S60);를 포함할 수 있다. Next, the present invention may include a molding step (S60) of mixing and stirring the organic mineral powder prepared by freeze-drying the organic mineral solution, water, excipients, preservatives, and functional additives to shape the product.
먼저, 상기 유기태미네랄 분말은 물 1L를 기준으로 25~100mg이 첨가될 수 있다. 여기에서, 만약 상기 유기태미네랄 분말이 2종 이상으로 준비된 경우 각 유기태미네랄 분말은 25mg 이상이 첨가되는 것이 바람직하며, 전체 총량은 300mg을 넘지 않는 것이 좋다. First, the organic mineral powder may be added in an amount of 25 to 100 mg per 1 L of water. Here, if two or more types of the organic mineral powder are prepared, it is preferable that each organic mineral powder be added in an amount of 25 mg or more, and the total amount should not exceed 300 mg.
부형제라 함은 유효성분을 포함하는 조성물을 제품의 형태로 만들어 주기 위한 일종의 담체로, 적당한 굳기나 형상을 주기 위해, 또는 주성분인 유효성분의 첨가량에 따라 일정 용량 또는 중량을 주어 취급하기 쉬운 크기로 만들기 위한 목적을 위해 첨가된다. An excipient is a type of carrier used to form a composition containing an active ingredient into a product form. It is added to provide an appropriate hardness or shape, or to make it into a size that is easy to handle by providing a certain capacity or weight depending on the amount of the active ingredient added, which is the main ingredient.
본 발명에서 상기 부형제는 상기 유기태미네랄 분말을 물과 함께 응고시켜 사료첨가제를 고상형 또는 반고상형(예를 들어 겔(gel))로 성형하기 위하여 첨가되는 것으로, 예를 들어 고상형 부형제로는 벤토나이트, 글루콘산나트륨(Sodium Gluconate) 중에서 선택된 하나일 수 있고, 반고상형 부형제로는 한천 가루, 콜라겐 가루, 피쉬콜라겐 가루, 젤라틴 가루 중에서 선택된 하나일 수 있다. 상기 유기태미네랄 분말은 겔 타입의 반고상형은 물론이고, 공극이 많아 다량의 수분을 머금을 수 있어서 고상형 제품성형 성형에도 유리한 장점이 있다. In the present invention, the excipient is added to coagulate the organic mineral powder together with water to form the feed additive into a solid or semi-solid form (e.g., a gel). For example, the solid excipient may be one selected from bentonite and sodium gluconate, and the semi-solid excipient may be one selected from agar powder, collagen powder, fish collagen powder, and gelatin powder. The organic mineral powder has the advantage of being advantageous not only in a gel-type semi-solid form, but also in solid-type product forming and forming because it has many pores and can hold a large amount of moisture.
상기 부형제는 물 1L를 기준으로 100~200g이 첨가될 수 있다. The above excipients can be added in an amount of 100 to 200 g per 1 L of water.
본 발명의 일 실시예에 따라 상기 부형제로서 한천 가루가 첨가될 수 있는데, 한천은 우뭇가사리 등의 해조류를 원료로 하여 해조류에서 추출한 점착물을 냉동건조시켜 제조되는 것으로, 성분의 대부분은 저칼로리의 식이섬유이다. 식이섬유는 콜레스테롤이나 고혈압을 내리는 작용이 있다. 식품 이외의 용도로는 식물의 조직배양이나 미생물배양시에 사용되는 한천배지로도 이용된다. 한천은 물에 용해되지 않기 때문에 상기 유기태미네랄 분말을 겔 형태로 유지시켜줄 수 있다. According to one embodiment of the present invention, agar powder may be added as the excipient. Agar is manufactured by freeze-drying an adhesive extracted from seaweed such as seaweed using seaweed as a raw material, and most of the ingredients are low-calorie dietary fiber. Dietary fiber has the effect of lowering cholesterol or high blood pressure. In addition to food, it is also used as an agar medium used in plant tissue culture or microbial culture. Since agar does not dissolve in water, it can maintain the organic mineral powder in a gel form.
또한, 상기 보존제는 미생물의 번식이나 부패를 막기 위한 것으로, 반려동물용 사료첨가제에 사용될 수 있는 성분이면 특별히 한정되지 않고 어떠한 것이든 사용할 수 있다. 예를 들어, 상기 보존제는 안식향산나트륨, 아세트산나트륨, 소듐라우릴설페이트 등을 사용할 수 있다. In addition, the preservative is intended to prevent the growth or decay of microorganisms, and any ingredient that can be used in pet feed additives is not particularly limited and can be used. For example, the preservative can be sodium benzoate, sodium acetate, sodium lauryl sulfate, etc.
또한, 본 발명에서 상기 기능성 첨가제는 반려동물의 건강을 증진시킬 뿐만아니라 기호도에 맞게 식감이나 향 등을 개선하기 위하여 첨가될 수 있다. 예를 들어, 상기 기능성 첨가제로서 비타민제와, 밀크씨슬추추물과, 루테인, 지아잔틴, 생선류, 오메가-3분말, 히알루론산, 베리류 추출물로 이루어지는 군 중에서 선택된 하나 또는 그 이상이 첨가될 수 있다. In addition, in the present invention, the functional additive may be added not only to promote the health of the companion animal, but also to improve the texture or flavor according to preference. For example, as the functional additive, one or more selected from the group consisting of vitamins, milk thistle extract, lutein, zeaxanthin, fish, omega-3 powder, hyaluronic acid, and berry extracts may be added.
비타민제는 비타민A, 비타민D, 비타민 B1, 비타민 B3, 비타민B6로 이루어지는 군 중에서 선택된 하나 또는 그 이상이 첨가될 수 있다. 이 중에서, 비타민A는 반려동물의 시력유지, 생식기능 유지(특히 번식), 골격의 성장 조절 및 성장에 관여하는 반드시 필요한 영양물질이다. 비타민D는 소장에서 칼슘 및 인의 흡수를 촉진하고 골격에 저장되어 있는 칼슘과 인을 동원하고 신장에서 칼슘 또는 인(P)의 재흡수를 증가시키는 등 칼슘과 인의 대사조절 기능을 가지고 있다. 비타민D가 부족할 경우 구루병, 골다공증, 골격이상, 식욕감퇴, 성장 및 사료효율 감소, 생식기능 저하 등의 임상증상을 나타나며 과잉급여 경우 식욕감퇴, 구토, 다뇨, 신장기능 저하 중상이 나타날 수 있다. 물 1L를 기준으로 상기 비타민A는 2~3mg, 비타민D는 0.01~0.0125mg, 비타민B1은 4~5mg, 비타민B3는 10~12mg, 비타민B6는 1~2mg이 첨가될 수 있다. Vitamin supplements may contain one or more selected from the group consisting of vitamin A, vitamin D, vitamin B1, vitamin B3, and vitamin B6. Among these, vitamin A is an essential nutrient that is involved in maintaining companion animals' eyesight, maintaining reproductive function (especially reproduction), regulating skeletal growth, and growth. Vitamin D has the function of regulating calcium and phosphorus metabolism, such as promoting the absorption of calcium and phosphorus in the small intestine, mobilizing calcium and phosphorus stored in the skeleton, and increasing the reabsorption of calcium or phosphorus (P) in the kidney. If vitamin D is insufficient, clinical symptoms such as rickets, osteoporosis, skeletal abnormalities, decreased appetite, decreased growth and feed efficiency, and decreased reproductive function may appear, and if it is overfed, decreased appetite, vomiting, polyuria, and severe renal dysfunction may appear. Based on 1L of water, 2~3mg of vitamin A, 0.01~0.0125mg of vitamin D, 4~5mg of vitamin B1, 10~12mg of vitamin B3, and 1~2mg of vitamin B6 can be added.
밀크씨슬추출물은 국화과의 한해살이풀인 흰무늬엉겅퀴(Silybum marianum) 꽃의 추출물로 영어로는 milk thistle인데, Milk라는 이름이 붙은 데에는 예전부터 산모가 젖이 잘 나오도록 하기 위해 먹었다는 데에서 유래되었다는 이야기가 있다. 상기 밀크씨슬은 간장 내 글루타치온(GSH)의 결핍을 방지함으로써 간 보호에 탁월한 효과가 있으며, 담즙의 흐름을 증진시켜 담석을 예방 혹은 치료하는 기능이 있으며, 더 나아가 간경변과 바이러스성 간염(hepatitis)을 포함한 일련의 간질환을 완화시키는 작용도 가지고 있다. 또한 비타민 C와 E보다 더욱 강력한 항산화제로 불안정한 자유기 분자들로부터의 조직 손상을 억제한다. 상기 밀크씨슬추추물은 물 1L를 기준으로 50~200mg이 첨가될 수 있다. Milk thistle extract is an extract of the flower of the white-spotted thistle (Silybum marianum), an annual plant in the Asteraceae family. Its English name is milk thistle. There is a story that the name "milk" comes from the fact that it was eaten by mothers to increase milk production in the past. The milk thistle is excellent for protecting the liver by preventing glutathione (GSH) deficiency in the liver, and has the function of preventing or treating gallstones by promoting the flow of bile. Furthermore, it has the effect of alleviating a series of liver diseases including cirrhosis and viral hepatitis. It is also a more powerful antioxidant than vitamins C and E, and suppresses tissue damage from unstable free radical molecules. The milk thistle extract can be added at 50 to 200 mg per 1 L of water.
크산토필은 C40H56O2를 갖는 물질로서, 화학구조상 카로티노이드 중 히드록시기(-OH), 카르보닐(-CO-), 에폭시드(-O-) 등의 형태로 산소를 포함하고 있다. 크산토필은 생물계에서 널리 존재하고 생체 내에서 카로티노이드의 산소화에 의해서 생성된다. 동물은 크산토필을 생성할 수 없고, 음식의 섭취량을 통해서 이를 얻는데, 예를 들면, 달걀노른자의 노란색은 닭이 섭취한 크산토필에 기인하는 것이다. 크산토필 그룹은 루테인(lutein), 제아잔틴(zeaxanthin) 및 α-크립토잔틴, β-크립토잔틴(cryptoxanthin)이며, 좁은 의미로는 루테인(lutein)을 말한다.Xanthophylls are substances with C 40 H 56 O 2 , and their chemical structure contains oxygen in the form of hydroxyl groups (-OH), carbonyl (-CO-), and epoxide (-O-) among carotenoids. Xanthophylls are widely present in the biological world and are produced by the oxygenation of carotenoids in the body. Animals cannot produce xanthophylls and obtain them through the intake of food. For example, the yellow color of egg yolks is due to the xanthophylls consumed by chickens. The xanthophylls group includes lutein, zeaxanthin, and α-cryptoxanthin, β-cryptoxanthin, and in a narrow sense, it refers to lutein.
크산토필은 망막의 중앙부분에서 기인한 노인성 시력감퇴를 줄이는 역할을 하며, 밝은 광선에 의한 망막조직의 손상을 막아주는데, 특히, 크산토필류 중 하나인 루테인(lutein)은 방세포, 난황 등에서 얻은 황색색소인 리포크롬을 말하는데, 크산토필과 공유결합을 하고 있다. 이러한 루테인은 몸속에서 자연적으로 생성되는 산소 자유래디컬(free radical)에 의해서 손상되는 눈의 내부를 보호하는 항산화제로서 활동한다. 또한 암종양을 공급하는 혈관의 성장을 줄여 암세포를 죽이며, 유방, 결장, 폐, 난소암, 피부암 예방에 효과가 있는 생리활성물질로 보고되고 있다.Xanthophylls play a role in reducing age-related vision loss originating in the central part of the retina and prevent damage to retinal tissue caused by bright light. In particular, lutein, one of the xanthophylls, refers to lipochrome, a yellow pigment obtained from retinal cells and egg yolk, and is covalently bonded with xanthophylls. This lutein acts as an antioxidant that protects the inside of the eye from damage by oxygen free radicals naturally produced in the body. It is also reported to be a physiologically active substance that kills cancer cells by reducing the growth of blood vessels that supply cancerous tumors, and is effective in preventing breast, colon, lung, ovarian, and skin cancer.
그리고 크산토필류 중 하나인 제아잔틴은 카로티노이드 알코올 중의 하나로 망막 안에 포함된 두 개의 카로티노이드(carotenoids) 중 하나로서, 옥수수, 사프란(saffron), 진한 녹색의 잎이 무성한 겨자, 순무. 케일, 콜라드와 같은 색깔을 가진 식물에 많다. 제아잔틴은 노화에 따른 시력감퇴, 백내장을 예방하며, 빛수용체 막에 지방산 과산화를 방지하며, 망막주변에 공급하는 혈관을 억제하는 역할을 하는 것으로 알려져 있다. 이러한 루테인과 제아잔틴은 최근 시력증진 효과가 있는 건강보조식품으로서 각광을 받고 있다. 상기 루테이과 지아잔틴은 2종 모두가 첨가되는 것이 좋으며, 물 1L를 기준으로 10~20mg이 첨가될 수 있다. And zeaxanthin, one of the xanthophylls, is one of the carotenoid alcohols and one of the two carotenoids contained in the retina, and is abundant in plants with colors such as corn, saffron, dark green leafy mustard, turnips, kale, and collards. Zeaxanthin is known to prevent vision loss and cataracts due to aging, prevent fatty acid peroxidation in the photoreceptor membrane, and suppress blood vessels supplying the retina. These lutein and zeaxanthin have recently been in the spotlight as health supplements with vision-enhancing effects. It is recommended to add both lutein and zeaxanthin, and 10 to 20 mg can be added per 1L of water.
생선류는 고양이과 동물들의 식욕을 돋우는 역할을 위해 첨가될 수 있으며, 예를 들어 생연어를 분쇄기에서 잘게 분쇄하여 사용할 수 있고, 또는 연어 성분이 함유된 오일을 사용할 수도 있다. 이러한 연어에 포함된 비타민A는 알러지 반응을 감소시키고, 눈질환의 예방 또는 치료에 효과가 있으며, 피부 및 모질에 영양을 주어 거친 피부에 윤기가 나게 하는 효과를 제공할 수 있다. 물 1L를 기준으로 50~100mg이 첨가될 수 있다. Fish can be added to stimulate the appetite of felines, for example, raw salmon can be finely ground in a grinder and used, or oil containing salmon ingredients can be used. Vitamin A contained in such salmon can reduce allergic reactions, is effective in preventing or treating eye diseases, and can provide nutrition to the skin and hair to make rough skin shiny. 50 to 100 mg can be added per 1 L of water.
오메가-3분말은 체내에 꼭 필요한 불포화 지방산으로 염증을 낮추고, 세포막을 튼튼하게 할 뿐만 아니라 눈 건강을 증진시키는 효과를 제공한다. 오메가-3는 DHA와 EPA로 이루어지는데, 이 중 DHA성분이 망막에 고농도로 존재하여 시각발달과 안구의 항염작용을 통해 눈 건강을 개선하게 된다. 물 1L를 기준으로 10~50mg이 첨가될 수 있다. Omega-3 powder is an essential unsaturated fatty acid in the body, which reduces inflammation, strengthens cell membranes, and improves eye health. Omega-3 is composed of DHA and EPA, and among these, DHA is present in high concentrations in the retina, improving eye health through visual development and anti-inflammatory effects on the eye. 10 to 50 mg can be added per 1L of water.
히알루론산(Hyaluronic acid)은 분자량에 따라 생리 활성 또는 기능성이 다르게 나타나는데, 고분자의 히알루론산은 인체 충진제(space-filler)로 사용되고, 혈관생성 억제(anti-angiogenic)활성, 면역 억제(Immunosuppressive) 활성 등의 기능성을 가지며, 중분자의 히알루론산은 면역 촉진(Immunostimulatory) 활성을 보이며, 저분자의 히알루론산은 세포사멸과 단백질 유도 등에 관여하는 것으로 알려져 있다. 또한, 보습효과, 물리적 마찰에 대한 윤활효과 및 세균 등의 침입에 대한 보호 효과 등이 우수하다. 물 1L를 기준으로 10~50mg이 첨가될 수 있다. Hyaluronic acid exhibits different physiological activities or functionality depending on its molecular weight. High molecular weight hyaluronic acid is used as a space-filler in the human body and has functions such as anti-angiogenic activity and immunosuppressive activity. Medium molecular weight hyaluronic acid exhibits immunostimulatory activity, and low molecular weight hyaluronic acid is known to be involved in apoptosis and protein induction. In addition, it has excellent moisturizing effects, lubricating effects against physical friction, and protective effects against invasion of bacteria, etc. 10 to 50 mg can be added per 1 L of water.
또한, 베리류의 일종인 빌베리(Vaccinium myrtillus fruit (Bilberry))는 유럽에서 수세기동안 생약 및 식재료로 사용된 월귤나무속 식물의 열매로서, 폴리페놀이 과량 함유되어 있어 항산화제, 항염증제로 사용되어 왔으며, 현저한 수렴효과를 가져서 입 및 점막의 염증 치료에 사용되고, 설사 및 치질의 치료에도 효능이 있다고 보고된 바 있다. 뿐만 아니라, 안토시아닌(Anthocynin), 나이아신, 비타민 A와 C 및 칼륨, 칼슘과 같은 무기염 등을 함유하고 있다. 물 1L를 기준으로 10~50mg이 첨가될 수 있다. Also, bilberry (Vaccinium myrtillus fruit (Bilberry)), a type of berry, is the fruit of the bilberry plant that has been used as a herbal medicine and food ingredient for centuries in Europe. It has been used as an antioxidant and anti-inflammatory agent due to its high content of polyphenols, and has been reported to have a remarkable astringent effect, so it is used to treat inflammation of the mouth and mucous membranes, and is also effective in treating diarrhea and hemorrhoids. In addition, it contains anthocyanin, niacin, vitamins A and C, and inorganic salts such as potassium and calcium. 10 to 50 mg can be added per 1 L of water.
실시예 2. Example 2.
포도당 40중량%와, 효모배양액 30중량%와, 옥수수전분28.5중량%와, 글루타민산 1.5중량%로 이루어지는 배지를 준비하였다. A medium consisting of 40 wt% glucose, 30 wt% yeast culture, 28.5 wt% corn starch, and 1.5 wt% glutamic acid was prepared.
다음으로, 상기 배지에 락토바실러스 플라타럼(Lactobacillus plantarum) 및 바실러스 아밀로리퀘파시언스(Bacillus amyloliquefaciencs)를 접종한 다음 혐기성인 락토바실러스 플라타럼과 호기성인 바실러스 아밀로리퀘파시언스를 동시 배양하기 위하여 온도 35℃, 공기 주입량 0.4vvm, 회전 속도 200 rpm으로 24시간 배양하여 락토바실러스 플란타럼(Lactobacillus plantarum) 함량이 2.9x108cfu/g이고, 바실러스 아밀로리퀘파시언스(Bacillus amyloliquefaciencs)의 함량이 2.8x108cfu/g인 복합균주 배양액을 배양하였다. 이후, 상기 복합균주 배양액을 원심분리를 통해 균주와 배양 상등액으로 분리하였다. Next, Lactobacillus plantarum and Bacillus amyloliquefaciencs were inoculated onto the medium, and then the medium was cultured at 35°C, an air injection amount of 0.4 vvm, and a rotation speed of 200 rpm for 24 hours to simultaneously culture anaerobic Lactobacillus plantarum and aerobic Bacillus amyloliquefaciencs, thereby culturing a composite strain culture having a Lactobacillus plantarum content of 2.9 x 10 8 cfu/g and a Bacillus amyloliquefaciencs content of 2.8 x 10 8 cfu/g. Thereafter, the composite strain culture was separated into strains and culture supernatant by centrifugation.
다음으로, 상기 배양 상등액 100중량부에 대하여 철(Fe) 2중량부를 첨가하여 무기태미네랄 용해액을 조성하였다. Next, 2 parts by weight of iron (Fe) was added to 100 parts by weight of the culture supernatant to form an inorganic mineral solution.
또한, 상기 배양 상등액 100중량부에 대하여 글리신 5중량부를 첨가한 다음, 상기 글리신의 유기태화 반응을 촉진시키기 위하여 글루탐산 5중량부를 더 첨가한 후 용해시켜 아미노산 용해액을 조성하였다. In addition, 5 parts by weight of glycine was added to 100 parts by weight of the culture supernatant, and then 5 parts by weight of glutamic acid was further added and dissolved to promote the organic passivation reaction of the glycine, thereby forming an amino acid solution.
다음으로, 상기 무기태미네랄 용해액과 아미노산 용해액을 1:1 중량비 비율로 혼합, 교반하여 유기태미네랄 용액을 조성한 다음, 동결건조기에서 -50℃로 24시간 동결건조시켜 분말형태를 갖는 반려동물용 사료첨가제(글리신 유기태화 철 분말)를 조성하였다. Next, the inorganic mineral solution and amino acid solution were mixed and stirred in a weight ratio of 1:1 to prepare an organic mineral solution, which was then freeze-dried in a freeze dryer at -50°C for 24 hours to prepare a powder-type pet feed additive (organo-passivated glycine iron powder).
다음으로, 물 1L에 상기 글리신 유기태화 철 분말 100g과, 한천가루 200g과, 비타민A 2mg, 비타민D 0.0125mg, 비타민B1 4mg, 비타민B3 11mg, 비타민B6 1.5mg, 밀크씨슬추출물 100mg, 루테인 및 지아잔틴 20mg, 연어가루 100mg, 오메가-3분말 30mg 히알루론산 50mg, 빌베리 추출물 30mg을 투입한 다음, 혼합 및 교반하여 겔(gel) 타입의 혼합물을 조성하였다. Next, 100 g of the organic glycine-passivated iron powder, 200 g of agar powder, 2 mg of vitamin A, 0.0125 mg of vitamin D, 4 mg of vitamin B1, 11 mg of vitamin B3, 1.5 mg of vitamin B6, 100 mg of milk thistle extract, 20 mg of lutein and zeaxanthin, 100 mg of salmon powder, 30 mg of omega-3 powder, 50 mg of hyaluronic acid, and 30 mg of bilberry extract were added to 1 L of water, and then mixed and stirred to form a gel-type mixture.
이후, 상기 혼합물 100중량부에 대하여 아세트산나트륨 0.5중량부를 첨가하여 본 발명의 다른 실시예에 따라 겔(gel) 타입의 반려동물용 사료첨가제를 조성하였다. Thereafter, 0.5 parts by weight of sodium acetate was added to 100 parts by weight of the mixture to form a gel-type pet feed additive according to another embodiment of the present invention.
상기와 같이 구성된 본 발명을 제공함으로써, 미네랄과 아미노산의 킬레이트 결합을 통해 반려동물의 체내 미네랄 흡수율이 향상되어 성장율을 증가시킬 수 있으며, 면역기능 개선효과를 기대할 수 있고, 체외로 배출되는 미네랄의 양을 줄일 수 있는 현저한 효과가 있다. By providing the present invention configured as described above, the absorption rate of minerals in the pet's body is improved through the chelate bond of minerals and amino acids, thereby increasing the growth rate, and an improvement in immune function can be expected, and there is a remarkable effect of reducing the amount of minerals excreted from the body.
이상에 설명한 본 명세서 및 청구범위에 사용되는 용어 및 단어는 통상적이거나 사전적인 의미로 한정해서 해석되어서는 아니 되며, 본 발명자는 그 자신의 발명을 가장 최선의 방법으로 설명하기 위해 용어의 개념을 적절하게 정의할 수 있다는 원칙에 입각하여 본 발명의 기술적 사상에 부합하는 의미와 개념으로 해석되어야만 한다.The terms and words used in this specification and claims described above should not be interpreted as limited to their usual or dictionary meanings, but should be interpreted as meanings and concepts that conform to the technical idea of the present invention based on the principle that the inventor can appropriately define the concept of the term in order to explain his own invention in the best way.
따라서, 본 명세서에 기재된 도면 및 실시 예에 도시된 구성은 본 발명의 가장 바람직한 하나의 실시 예에 불과할 뿐이고, 본 발명의 기술적 사상을 모두 대변하는 것이 아니므로, 본 출원시점에 있어서 이들을 대체할 수 있는 다양한 균등물과 변형 예들이 있을 수 있음을 이해하여야 한다.Therefore, the configurations depicted in the drawings and embodiments described in this specification are only the most preferred embodiment of the present invention, and do not represent all of the technical ideas of the present invention. Therefore, it should be understood that there may be various equivalents and modified examples that can replace them at the time of filing this application.
Claims (6)
상기 복합균주 배양액을 복합균주와 배양 상등액으로 분리한 후 상기 배양 상등액을 별도로 선별하는 배양 상등액 준비단계(S20)와;
상기 배양 상등액에 무기태미네랄을 용해시켜 무기태미네랄 용해액을 조성하는 무기태미네랄 용해액 조성단계(S30)와;
상기 배양 상등액에 아미노산을 용해시켜 아미노산 용해액을 조성하는 아미노산 용해액 조성단계(S40)와;
상기 무기태미네랄 용해액과 아미노산 용해액을 혼합하여 킬레이트 반응을 통해 유기태미네랄 용액으로 조성하는 유기태미네랄 용액 조성단계(S50)와;
상기 유기태미네랄 용액을 동결건조시키는 동결건조단계(S60);를 포함하는 것을 특징으로 하는 반려동물용 사료첨가제의 제조방법.
A complex strain culture solution in which a medium comprising 94 to 98 wt% of purified water, 1 to 3 wt% of glucose, 0.5 to 2 wt% of yeast extract, 0.1 to 0.5 wt% of sodium chloride (NaCl), and 0.1 to 0.5 wt% of potassium hydrogen phosphate (K 2 HPO 4 ) is sterilized at 120 to 125°C for 15 minutes, lactic acid bacteria and Bacillus subtilis are inoculated into the medium, and cultured for 24 to 36 hours at a temperature of 30 to 37°C, an air injection amount of 0.2 to 0.4 vvm, and a rotation speed of 50 to 200 rpm. In order to promote the growth of the lactic acid bacteria and Bacillus subtilis, one or more of a seawater-derived mineral concentrate, an aqueous sulfur dispersion, or an aqueous illite dispersion is added to the medium to culture the complex strain culture solution. Incubation stage (S10) and;
A culture supernatant preparation step (S20) in which the above complex strain culture solution is separated into a complex strain and a culture supernatant, and the above culture supernatant is separately selected;
A step (S30) of forming an inorganic mineral solution by dissolving inorganic minerals in the culture supernatant;
An amino acid solution composition step (S40) for dissolving amino acids in the culture supernatant to create an amino acid solution;
An organic mineral solution composition step (S50) of mixing the above inorganic mineral solution and amino acid solution to form an organic mineral solution through a chelating reaction;
A method for manufacturing a pet feed additive, characterized by including a freeze-drying step (S60) of freeze-drying the organic mineral solution.
상기 복합균주 배양액을 복합균주와 배양 상등액으로 분리한 후 상기 배양 상등액을 별도로 선별하는 배양 상등액 준비단계(S20)와;
상기 배양 상등액에 무기태미네랄을 용해시켜 무기태미네랄 용해액을 조성하는 무기태미네랄 용해액 조성단계(S30)와;
상기 배양 상등액에 아미노산을 용해시켜 아미노산 용해액을 조성하는 아미노산 용해액 조성단계(S40)와;
상기 무기태미네랄 용해액과 아미노산 용해액을 혼합하여 킬레이트 반응을 통해 유기태미네랄 용액으로 조성하는 유기태미네랄 용액 조성단계(S50)와;
상기 유기태미네랄 용액을 동결건조시키는 동결건조단계(S60);를 포함하는 것을 특징으로 하는 반려동물용 사료첨가제의 제조방법.
A step (S10) of culturing a complex strain culture solution, wherein a medium composed of 30 to 50 wt% of glucose, 20 to 40 wt% of yeast culture, 25 to 30 wt% of corn starch, and 1 to 5 wt% of glutamic acid is sterilized at 120 to 125°C for 15 minutes, lactic acid bacteria and Bacillus subtilis are inoculated into the medium, and then cultured at a temperature of 30 to 37°C, an air injection amount of 0.2 to 0.4 vvm, and a rotation speed of 50 to 200 rpm for 24 to 36 hours, and wherein one or more of a seawater-derived mineral concentrate, an aqueous sulfur dispersion, or an aqueous illite dispersion is added to the medium to promote the growth of the lactic acid bacteria and Bacillus subtilis, thereby culturing a complex strain culture solution;
A culture supernatant preparation step (S20) in which the above complex strain culture solution is separated into a complex strain and a culture supernatant, and the above culture supernatant is separately selected;
A step (S30) of forming an inorganic mineral solution by dissolving inorganic minerals in the culture supernatant;
An amino acid solution composition step (S40) for dissolving amino acids in the culture supernatant to create an amino acid solution;
An organic mineral solution composition step (S50) of mixing the above inorganic mineral solution and amino acid solution to form an organic mineral solution through a chelating reaction;
A method for manufacturing a pet feed additive, characterized by including a freeze-drying step (S60) of freeze-drying the organic mineral solution.
상기 배양 상등액 100중량부에 대하여 크롬(Cr), 아연(Zn), 철(Fe), 구리(Cu), 셀레늄(Se), 망간(Mn), 붕소(B), 티타늄(Ti), 게르마늄(Ge), 칼슘(Ca)으로 이루어진 군 중에서 선택된 어느 하나의 무기태 미네랄 1~10중량부를 용해시켜 무기태미네랄 용해액을 조성하며,
상기 배양 상등액의 pH를 조절하여 상기 무기태미네랄의 용해를 촉진시킬 수 있도록 유기산이 더 첨가되는 것을 특징으로 하는 반려동물용 사료첨가제의 제조방법.
In the first or second paragraph, the step of forming the inorganic mineral solution (S30) is
In 100 parts by weight of the culture supernatant, 1 to 10 parts by weight of any one inorganic mineral selected from the group consisting of chromium (Cr), zinc (Zn), iron (Fe), copper (Cu), selenium (Se), manganese (Mn), boron (B), titanium (Ti), germanium (Ge), and calcium (Ca) is dissolved to form an inorganic mineral solution.
A method for manufacturing a pet feed additive, characterized in that an organic acid is further added to adjust the pH of the culture supernatant to promote the dissolution of the inorganic minerals.
상기 배양 상등액 100중량부에 대하여 리신, 아르기닌, 히스티딘, 시스테인, 페닐 알라닌, 타이로신, 메티오닌, 글리신으로 이루어진 군 중에서 선택된 하나의 아미노산 0.1~10중량부를 용해시키는 것을 특징으로 하는 반려동물용 사료첨가제의 제조방법.
In the first or second paragraph, the amino acid solution composition step (S40) is
A method for producing a pet feed additive, characterized in that 0.1 to 10 parts by weight of one amino acid selected from the group consisting of lysine, arginine, histidine, cysteine, phenylalanine, tyrosine, methionine, and glycine is dissolved in 100 parts by weight of the culture supernatant.
상기 아미노산은 글리신이며,
상기 글리신은 배양 상등액 100중량부에 대하여 0.1~10중량부가 첨가되고,
상기 무기태미네랄 용해액과의 킬레이트 반응을 촉진시킬 수 있도록 글루탐산이 더 첨가되는 것을 특징으로 하는 반려동물용 사료첨가제의 제조방법.
In the first or second paragraph, in the amino acid solution composition step (S40),
The above amino acid is glycine,
The above glycine is added in an amount of 0.1 to 10 parts by weight per 100 parts by weight of the culture supernatant.
A method for manufacturing a pet feed additive, characterized in that glutamic acid is further added to promote a chelating reaction with the above-mentioned inorganic mineral solution.
A method for manufacturing a pet feed additive, characterized in that it comprises a step of mixing and stirring the organic mineral powder manufactured in the freeze-drying step (S60), water, an excipient, a preservative, and a functional additive in claim 1 or 2.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020230070071A KR102722620B1 (en) | 2023-05-31 | 2023-05-31 | Manufacturing method of animal feed additives |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020230070071A KR102722620B1 (en) | 2023-05-31 | 2023-05-31 | Manufacturing method of animal feed additives |
Publications (1)
Publication Number | Publication Date |
---|---|
KR102722620B1 true KR102722620B1 (en) | 2024-10-28 |
Family
ID=93287796
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020230070071A KR102722620B1 (en) | 2023-05-31 | 2023-05-31 | Manufacturing method of animal feed additives |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102722620B1 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20170000755A1 (en) | 2015-07-02 | 2017-01-05 | Novus International Inc. | Antimicrobial compositions and uses thereof |
US20180070611A1 (en) | 2015-03-25 | 2018-03-15 | Feng Wan | Amino acid animal feed composition |
KR101929492B1 (en) * | 2018-02-06 | 2019-03-14 | 주식회사 바이오에이엠 | Animal feed additive and manufacturing method thereof |
-
2023
- 2023-05-31 KR KR1020230070071A patent/KR102722620B1/en active IP Right Grant
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20180070611A1 (en) | 2015-03-25 | 2018-03-15 | Feng Wan | Amino acid animal feed composition |
US20170000755A1 (en) | 2015-07-02 | 2017-01-05 | Novus International Inc. | Antimicrobial compositions and uses thereof |
KR101929492B1 (en) * | 2018-02-06 | 2019-03-14 | 주식회사 바이오에이엠 | Animal feed additive and manufacturing method thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106721843B (en) | Double-bacterial protein solid beverage | |
CN103704530B (en) | A kind of loach seedling special compound feed | |
CN105452442A (en) | Methods of producing algal cell cultures and biomass, lipid compounds and compositions, and related products | |
CN108056325B (en) | Sea water black porgy feed with immunity enhancing function | |
CN104663246A (en) | Production method of edible mushroom with rich selenium and high calcium | |
CN107223986A (en) | A kind of selenium-rich health-care polypeptide product and preparation method thereof | |
Desai et al. | Spirulina: The wonder food of the 21st Century | |
CN107348229A (en) | A kind of catfish feed eating belt agent and preparation method thereof | |
KR20090021844A (en) | Additive for fishes feed using photosynthetic bacteria and feed comprising it | |
CN111387393A (en) | Beverage containing small molecular peptide, resveratrol and anthocyanin and preparation method thereof | |
CA2583449A1 (en) | A method of cultivating animals to develop a desired color and to increase their rate of growth | |
KR102722620B1 (en) | Manufacturing method of animal feed additives | |
KR101481484B1 (en) | Feed for abalon | |
CN102224882B (en) | Preparation method for feed additive with antioxidation function | |
KR101358036B1 (en) | method for manufacturing a ferment feeds including Japanese Lacquer | |
CN108850667A (en) | A kind of microorganism Remixed agent | |
KR20110138607A (en) | Manufacturing method for feedstuff containing by-product of salted fish sauce | |
CN106805007A (en) | A kind of high yield catfish feed eating belt agent and preparation method thereof | |
KR20040069487A (en) | Feed including garlic for poultry | |
CN109874937A (en) | The low brotein equilibrium nutrition selenium-rich zoology feed of store pig | |
EP3031904B1 (en) | Composition comprising salt and microalgae biomass, process of its production and uses (with variants) | |
CN106578582A (en) | Feed for young ostriches and preparation method of feed | |
KR102699079B1 (en) | Nanoproducts containing vitamins a, d3 and e, and nutritional supplements for animals using the same | |
KR102609443B1 (en) | Feed for companion animals including black soldier fly, juice pieces and egg shell | |
KR20170083747A (en) | Feed additives for abalone |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GRNT | Written decision to grant |